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Summary 
 
Alzheimer’s disease (AD) is a fast growing global problem. AD is a form of dementia 
characterised by the progressive loss of cognitive abilities. Pathologically, the disease is 
defined by two neuropathological hallmarks: neurofibrillary tangles and amyloid-β plaques. 
Plaques appear to be toxic to brain tissue and are surrounded by activated microglia and 
astrocytes, dystrophic neurites and neurons under oxidative stress. 
When plaques first develop, they are generally small, but in advanced AD, plaques can be 
much larger. How small plaques may develop into large plaques is still unclear. A number of 
studies have shown that small plaques grow uniformly over time to give rise to larger 
plaques. However, this study investigates an alternative hypothesis: that clusters of multiple 
small plaques merge over time to form large plaques. This hypothesis was inspired by a study 
that showed that plaques do not deposit in random locations within the brain parenchyma, but 
rather form in clusters and that these plaque clusters get bigger over time. The aim was to 
investigate the clustering of plaques in vivo, and follow these clusters over time to see 
whether they merge together to form a single, larger plaque. 
This study employed a 2-stage staining technique to follow individual plaques in APPPS1 
transgenic mice over time. The fluorescent, amyloid-binding dye Methoxy-X04 was injected 
into the mice at Day 0 of the experiment. Methoxy-X04 crosses the blood brain barrier and 
binds stably to plaques for several months and thus labelled the original plaque population. 
Following 1 day, 1 month or 4 month incubation periods, acute in vivo plaque imaging was 
performed or the mice sacrificed for post mortem analysis. Antibodies against amyloid-β 
labelled the state of the plaques at these later time points. Hence this procedure enabled 
comparison of individual plaque status at different time points and the identification of new 
plaques that had developed over the incubation time. 
Detailed analysis of the new and pre-existing plaques revealed two key results. Firstly, that 
new plaques are more likely to form very close (< 40 µm) to a pre-existing plaque than at 
further distances. New plaques depositing very close to other plaques formed clusters of 
plaques in the tissue. Secondly, that clusters of close plaques can fuse over time to form a 
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single large plaque. These two key results provide compelling evidence for a clustering 
hypothesis of large plaque formation and growth. 
Together, these data provide in vivo support for the clustering hypothesis by which clusters 
of small plaques merge together to form single plaques over time. This work expands our 
understanding of how plaques form and develop in AD and could inform the understanding 
of plaque clearance strategies to combat AD pathological changes in the brains of patients. 
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Introduction 
 
1. Alzheimer’s Disease 
Alzheimer’s disease (AD) is the most common form of dementia worldwide (Selkoe, 2001) 
accounting for 60-80% of all dementia cases (Thies & Bleier, 2011). Once over the age of 85, 
the chance of developing AD is 25-40% (Golde et al., 2011) and on a global scale, AD is 
currently estimated to affect 26.6 million people (Brookmeyer et al., 2011). As the human 
population ages, current projections forecast that, by 2050, a total of 100 million people will 
suffer from AD (Golde et al., 2011). This is a worrying prediction as the economic burden, in 
turns of palliative care and loss of economic contribution for so many patients and their 
carer-givers will be immense. To date there is no treatment for AD, only symptomatic relief 
in the mild to moderate stages of the disease (Holtzman et al., 2011). With the number of AD 
patients growing day by day, the need to find etiological clues and develop disease-modifying 
treatments is increasingly urgent. 
AD is a disease recognised by the gradual worsening of memory, attention and other 
intellectual abilities. AD contains a long, pre-symptomatic phase and pathological changes in 
the brain are thought to begin decades before cognitive problems manifest (Jack Jr et al., 
2010). The time course for AD from first clinical presentation to death is typically 7 to 10 
years (Holtzman et al., 2011). AD patients generally first notice a loss of short-term and 
spatial memory, reduced attention and deficient problem-solving skills (Holtzman et al., 
2011). Over the progression of the disease, memory, cognition and functional ability further 
diminish, frequently accompanied by symptoms of depression, anxiety and paranoia. In 
advanced stages of AD, patients are unable to perform basic everyday tasks and require 
intensive care, ultimately becoming entirely bed-bound. Patients often die of concomitant 
secondary complications associated with inertia, such as pneumonia (Thies & Bleier, 2011). 
1.1. Pathological Hallmarks of Alzheimer’s Disease 
Alzheimer’s disease was first identified as a unique neurological disorder in 1907 by Alois 
Alzheimer (Figure 1, (Alzheimer, 1907; Stelzmann et al., 1995)). He observed the two 
prominent cerebral hallmarks of the disease that are still used for post mortem diagnosis 
today – neurofibrillary tangles and amyloid plaques (Figure 2).  
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Figure 1: The identification of Alzheimer’s Disease. Alois Alzheimer (left) and his first patient 
diagnosed with Alzheimer’s disease, Augusta Deter (right). Images in the public domain. 
 
Neurofibrillary tangles are abnormal intracellular structures mainly consisting of 
hyperphosphorylated tau protein (Grundke-Iqbal et al., 1986). Tau is a microtubule stabilising 
protein that is normally bound to the microtubules and forms an integral part of the cell 
structure. However, in AD, tau becomes hyperphosphorylated so that it no longer binds to 
microtubules (Drechsel et al., 1992) and aggregates inside the cell, eventually forming 
neurofibrillary tangles. Neurofibrillary tangles are often called the ‘tombstones’ of neurons as 
they are all that remains after the original cell has succumbed to the disease (Gendreau & 
Hall, 2013). What causes tau to be hyperphosphorylated and how amyloid-β (Aβ) peptide 
might be involved is still a matter of debate. Aggregated Aβ peptide is the main ingredient in 
the second hallmark of AD, amyloid-β plaques (Figure 2). Amyloid-β plaques are mainly 
found in the parenchyma, but also deposits around cerebral blood vessels to form cerebral 
amyloid angiopathy (CAA) (Attems et al., 2010). Amyloid plaques within the brain 
parenchyma are the main subject of this thesis and will be described in more detail in 
subsequent sections. 
14 
 
 
 
Figure 2: The pathological hallmarks of Alzheimer’s disease.  Neurofibrillary tangles (black 
semi-circle; upper white arrow) and amyloid plaques (dark brown, fibrous mass; lower white 
arrow) are the two major neuropathological hallmarks of Alzheimer’s disease. Image taken from 
(Schellenberg & Montine, 2012). 
 
1.2. Generation of Amyloid-β from its Precursor Protein 
Aβ peptide, the major component of amyloid plaques, is produced by intramembrane 
cleavage of the Amyloid Precursor Protein (APP). APP (Figure 3a) is a highly conserved 
transmembrane protein and its cleavage follows two major enzymatic pathways; the 
non-amyloidogenic pathway and the amyloidogenic pathway (Figure 3).  
In the non-amyloidogenic pathway, APP is cleaved at the cell surface by the enzyme 
α-secretase within the Aβ region to generate soluble APPα (sAPPα) and the α-c-terminal 
fragment (αCTF). As this cleavage occurs within the Aβ amino acid stretch, Aβ is not 
produced by this cleavage pathway (Figure 3b). The αCTF is further cleaved by γ-secretase to 
produce p3 and the APP intracellular domain (AICD, Figure 3c).  
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In the amyloidogenic pathway, APP is first cleaved in the endosomal compartment by β-
secretase to generate the sAPPβ fragment and the βCTF (Figure 3d), and subsequently 
cleaved by γ-secretase to release the Aβ peptide into the extracellular space (Figure 3e) and 
the AICD intracellularly. The γ-secretase enzyme can cleave APP at different sites to give 
different species of Aβ: 38, 40 and 42 amino acids in length being the most common. Aβ is 
then released into the endosomal lumen or into the extracellular space (O'Brien & Wong, 
2011).  Aβ40 is the most abundant Aβ species produced (Seubert et al., 1992). However, in 
AD patients, Aβ42 is the most abundant Aβ species found in plaques (Roher et al., 1993). 
Aβ42 has the greatest propensity to aggregate of all the Aβ species as shown by in vitro 
experiments (Snyder et al., 1994) and these aggregated Aβ species can form fibrils that give 
rise to plaques. Therefore, an increase in Aβ42 could directly promote AD pathological 
processes. 
 
 
Figure 3: Processing of APP by the 3 secretases. In the non-amyloidogenic pathway, APP (a) is 
cleaved by α-secretase to generate sAPPα and αCTF (b) and then by γ-secretase to release p3 
and the AICD (APP intracellular domain). In the amyloidogenic pathway, APP (a) is cleaved 
first by β-secretase to generate sAPPβ and the βCTF (d) and subsequently by γ-secretase to 
release Aβ into the extracellular space and AICD intracellularly (e). 
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The three secretases have been characterised molecularly. ADAM10 was identified as an α-
secretase (Kuhn et al., 2010; Lammich et al., 1999) and, when over-expressed in APP 
transgenic mice, increase sAPPα and decrease Aβ42 production and plaque deposition 
(Postina et al., 2004). BACE1 is a β-secretase (Willem et al., 2009) and BACE1 knock-out 
APP transgenic mice do not deposit any plaques (Luo et al., 2003). γ-secretase is a complex 
of 4 different proteins: presenilin (PS), Nicastrin, APH-1 and PEN-2 that are all required for 
its enzymatic function (Edbauer et al., 2003). 
The physiological functions of APP and its cleavage products are largely unknown or highly 
debated. APP is a ubiquitously expressed protein and highly conserved, yet the role of this 
protein remains elusive. Mice overexpressing APP have enlarged cortical neurons, suggestive 
of a neurotrophic effect (Oh et al., 2009), while APP knockout mice had reduced brain 
weight, deficient LTP and impaired spatial navigation in behavioural tests (Ring et al., 2007). 
sAPPα also appears to be beneficial to neurons; sAPPα protects neurons against stress 
(Mattson et al., 1993) and reduces neuronal damage following traumatic brain injury 
(Thornton et al., 2006). CTFα and –β have no known physiological function (Chow et al., 
2010). Research suggests a role for AICD in transcription, apoptosis and cytoskeletal 
dynamics, but the data are inconclusive and many questions remain open (Müller et al., 
2008). It is important to continue research into the physiological functions of these proteins 
as any therapy aimed at altering these cleavage pathways could have unintended side-effects. 
1.3. Genetics of Alzheimer’s Disease 
There are two main categories of AD: familial and sporadic. Familial AD (FAD) accounts for 
<1% of all AD cases (Morris et al., 2012) and is associated with heritable autosomal 
dominant mutations. The majority of AD cases are classified as sporadic AD (SAD) where no 
clear genetic cause is implicated. 
Familial AD (FAD) patients have an earlier onset and faster progression than SAD cases. 
Some forms of FAD are caused by mutations in the amyloid precursor protein (APP) from 
which Aβ is cleaved. All 31 FAD APP mutations are found in a 54 amino acid segment in 
and around the Aβ peptide sequence and effect the amount or type of Aβ produced; this 
generally leads to increased Aβ aggregation and plaque formation (Schellenberg & Montine, 
2012). For example, some mutations lead to an increase in the amyloidogenic processing of 
APP (Haass et al., 1994). Many APP mutation sufferers have specific neuropathological 
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characteristics; they may develop more plaques than SAD patients (Ishii et al., 2001) or 
display overly CAA-dominated pathology (Natté et al., 2001). 
Mutations in subunits of the γ-secretase enzymatic complex that cleaves APP – called 
Presenilin 1 or 2 (PS1 or PS2) - are also known to cause FAD. These mutations primarily 
alter the transmembrane domains of these proteins (O'Brien & Wong, 2011) and effect the 
enzymatic processing of APP. PS mutations can also increase the amount of plaques (Ishii et 
al., 2001) and tau deposits (Shepherd et al., 2004) found in the brains of patients carrying 
these mutations compared with the more common SAD neuropathology. 
Sporadic AD (SAD) patients generally have a later onset of the disease than patients with 
FAD, typically first presenting symptoms after the age of 65, and the specific cause of SAD 
is largely unknown. Genomic studies have, however, identified a number of risk factors that 
alter the chance of developing SAD. The most common risk factor for SAD is the APOE4 
allele (Strittmatter et al., 1993) which is present in 10-20% of the population (Singh et al., 
2006). Heterozygous carriers have three-fold increase in risk of AD, while for homozygous 
individuals, the risk increases 12-fold (Kim et al., 2009). The ApoE4 protein degrades Aβ 
less than other APOE variants (Small & Duff, 2008), thereby most likely increasing the rate 
of AD pathology. Indeed, expression of APOE4 in APP transgenic mice exacerbated the AD 
pathology of these mice compared to control mice (Hudry et al., 2013).  A correlation was 
also found between sortilin-related receptor 1 (SORL1) mutations and SAD risk (Reitz et al., 
2011; Rogaeva et al., 2007). SORL1 is involved in a cellular transport pathway important for 
Aβ generation (Lane et al., 2010), although exactly how this would then increase the risk of 
AD is still unclear. 
Rare heterozygous mutations in the TREM2 protein have been linked to an increased risk of 
SAD (Guerreiro et al., 2013; Jonsson et al., 2013). TREM2 is expressed in microglia and 
regulates microglial phagocytosis (Guerreiro et al., 2013). If TREM2 function is impaired by 
these SAD-linked mutations, then impaired microglia phagocytosis reducing the clearance of 
Aβ could explain the increased risk of SAD.  
A recent meta-analysis of genome wide association studies (GWAS) involving over 70,000 
individuals’ genomes discovered a number of new AD risk factors. These genetic risk factors 
implicate a number of factors in the susceptibility to AD; e.g. inflammation, synaptic function 
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and axonal transport (Lambert et al., 2013). These new factors could yield some exciting 
lines of investigation into the etiology and modification of AD. 
Genetic analysis also revealed a mutation protective against AD; a study of an Icelandic 
population found that an APP mutation decreased the risk of developing AD (Jonsson et al., 
2012). This study sheds light on a cellular mechanism that protects against AD, and may lead 
to new insights into preventative therapies. 
1.4. Mouse Models of Alzheimer’s Disease 
There are many different transgenic animals used to investigate AD; from fish, flies and 
worms to rats and mice. Although useful for investigating certain questions, fish, fly and 
worm models are very physiologically different to AD patients. Rodents have a much more 
comparable physiology and, of particular interest when studying AD, a similar gross brain 
anatomy. Mice are easy to breed and house and the technology to create transgenic mouse 
lines is well established. Transgenic mice are therefore an extremely useful model to 
investigate aspects of AD. 
Knowledge about FAD-causing autosomal dominant mutations has been used to recapitulate 
AD pathology in mice. The first transgenic mouse models used to study AD expressed human 
APP mutations. For example, the Tg2576 mouse expresses APP 695 with the Swedish double 
mutation (Hsiao et al., 1996), the APP23 mouse expresses APP 751 with the Swedish double 
mutation (Sturchler-Pierrat et al., 1997), while the PDAPP mouse expresses the V717F APP 
mutation (Games et al., 1995). All three APP mouse models develop Aβ plaques, gliosis and 
dystrophic neurites. PS1 mutant mouse lines have been generated (Elder et al., 2010), but fail 
to develop plaque pathology. Only when crossed with an APP mutant line, do they develop 
plaques and the onset of plaque pathology is even accelerated (Holcomb et al., 1998).  
Mouse models only recapitulate limited aspects of human AD patient pathology and 
symptoms and as such are incomplete models of AD (Radde et al., 2008). For example, 
neurofibrillary tangle pathology is only seen when an additional tau mutation (discovered in 
frontotemporal dementia patients) is expressed. Crossing the Tg2576 mouse with a mouse 
expressing Tau with the P301L mutation produced the same amount of plaques as Tg2576 
mice, but the neurofibrillary tangle pathology was earlier and more extensive than the pure 
Tau P301L mouse (Lewis et al., 2001). Another model, the 3xTg mouse expresses APP, PS1 
19 
 
and tau mutations and develops plaques and neurofibrillary tangles (Oddo et al., 2003). 
Furthermore, the gross neuronal loss associated with AD (Figure 4) is strikingly absent from 
mouse models of AD (Radde et al., 2008). Nevertheless, incomplete mouse models are very 
useful to investigate certain aspects of the disease, for example amyloid plaque development, 
in isolation without the added complication of comorbid pathology.  
1.5. Neuroinflammation in Alzheimer’s Disease 
As well summarised in a review entitled “Inflammation in Alzheimer disease: driving force, 
bystander or beneficial response?” (Wyss-Coray, 2006), there is no consensus as to the 
consequences of inflammation on the pathology of AD whether positive or detrimental. 
Inflammation is an important defence mechanism against invading pathogens and vital for the 
clearance of dead cell debris. In the central nervous system (CNS), neuroinflammation is 
mainly carried out by two glial cell types: microglia and astrocytes that appear to change 
during the course of AD. Microglia cluster around plaques in AD (Figure 4 (Itagaki et al., 
1989)) and, in APP transgenic mice, are larger around plaques (Frautschy et al., 1998) and 
display an altered phenotype (Koenigsknecht-Talboo et al., 2008). Pharmacological 
suppression of microglial activation decreased the plaque deposition and hippocampal 
neuronal loss induced by Aβ42 infusion (Craft et al., 2004). Microglia appear to regulate 
plaques as a study in APP transgenic mice revealed that microglia surrounding plaques 
internalise Aβ, removing it from the plaque (Bolmont et al., 2008). Yet a study that ablated 
90% of the microglia in APP transgenic mice, did not show any alteration in plaque load or 
plaque size (Grathwohl et al., 2009). Therefore, the precise role microglia play in AD is still 
unclear. 
Astrocytes are closely associated with synapses and play an active role in removing 
neurotransmitters from the synaptic cleft. This means that any perturbation in astrocyte 
functions could have damaging consequences for synaptic function and neuron viability. 
Plaques attract astrocytes which encircle the plaques (Figure 4 (Sofroniew & Vinters, 2010)) 
and astrocytes have also been shown to take up Aβ for degradation and even clear tissue of 
plaques (Wyss-Coray et al., 2003). Whether this Aβ clearing property could be harnessed to 
protect against AD or whether this would be detrimental to the synaptic functions of 
astrocytes remains unsolved. 
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A further component of neuroinflammation is the complement system. The complement 
system is made up of a number of complex molecular pathways that serve to ‘complement’ 
the cellular part of the immune system. It performs a number of tasks including stimulating 
inflammatory pathways, assisting phagocytosis and forming the membrane attack complex 
(MAC). The MAC is an assembly of complement proteins that inserts into membranes and 
induces membrane lysis. The complement system appears to be involved in the pathology of 
AD as complement proteins are found within plaques (Figure 4 (Eikelenboom et al., 1988)). 
MAC components are found within dystrophic neurites suggesting that the MAC may be 
active in these cells and contribute to the  degeneration of these neurons by membrane lysis 
(Webster et al., 1997). Finally, in vitro aggregates of Aβ strongly activate the complement 
system showing that Aβ may trigger the complement system involvement in AD (Rogers et 
al., 1992). 
 
 
Figure 4: Neuroinflammation in Alzheimer’s Disease. Microglia and astrocytes are recruited to 
amyloid plaques. Complement proteins associate with extracellular plaques and interneuronal 
neurofibrillary tangles. 
 
Epidemiological studies found a link between long term NSAID (non-steroidal anti-
inflammatory drugs) use, generally taken to reduce the symptoms of rheumatoid arthritis, 
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reduced the risk of AD (McGeer et al., 1990; Vlad et al., 2008). This link appeared to be a 
way of protecting against AD, indeed APP transgenic mice treated with Ibuprofen had fewer 
plaques and dystrophic neurites (Lim et al., 2000) and curcumin treatment reduced gliosis 
and plaque load (Lim et al., 2001). Despite these promising data, clinical trials of NSAID 
treatment in AD patients failed to show a beneficial effect (de Jong et al., 2008; Pasqualetti et 
al., 2009). Nevertheless, there seems to be an enigmatic link between inflammation and AD 
risk and pathology that warrants further exploration. 
1.6. Neuronal and Synaptic Loss in Alzheimer’s Disease 
AD is characterised by a massive loss of neurons (Holtzman et al., 2011), most strikingly 
demonstrated by the gross loss of cortical grey matter that results in enlarged ventricles and 
severe brain shrinkage in post mortem samples of AD patients (Figure 5). Structural MRI 
(magnetic resonance imaging) studies have demonstrated a correlation between the extent of 
cortical atrophy and the severity of cognitive symptoms (Jack Jr et al., 2010). Moreover, 
functional imaging, e.g. FDG-PET (fluorodeoxyglucose - positron emission tomography), 
shows functional changes in the brain of AD patients. FDG-PET is a measure of net brain 
metabolism and indicates synaptic activity. AD patients have decreased FDG-PET uptake 
compared to control patients, implying a reduction in synaptic activity. This decreased uptake 
correlates well with the patients’ cognitive decline (Minoshima et al., 1997) and correctly 
predicts post mortem AD diagnosis (Hoffman et al., 2000). Progressive neuronal and synaptic 
deficiency in AD is thought to underlie the cognitive decline observed throughout the disease 
and can be used to monitor disease progression. 
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Figure 5: Cortical atrophy in advanced Alzheimer’s disease.  An Alzheimer’s disease patient 
typically has substantial grey matter atrophy.  From the Alzheimer’s society (www.alz.org). 
 
1.7. Lifestyle Risk Factors Associated with Alzheimer’s Disease 
Age is the most important risk factor for AD, but a number of lifestyle factors are associated 
with a modified risk of AD (Ballard et al., 2011). For example, obesity (Beydoun et al., 
2008), regular smoking (Rusanen et al., 2011), and heavy alcohol consumption (Tyas, 2001) 
have all been linked to an increased risk of AD. Evidence has also come from animal studies 
for lifestyle risk factors for AD; APP transgenic mice fed a high-fat diet (Ho et al., 2004) or 
exposed to daily cigarette smoke (Moreno-Gonzalez et al., 2013) had exacerbated AD-related 
pathology. Regular physical exercise has a preventative effect in AD (Hamer & Chida, 2009) 
and numerous studies provide evidence that a high cognitive reserve – a measure of 
education, occupation and mental activities – delays the onset of AD symptoms in patients 
(Valenzuela & Sachdev, 2006). Supporting this correlation, mice expressing AD transgenes 
exposed to an enriched environment showed a decrease in AD pathology compared to mice 
housed in a standard environment (Lazarov et al., 2005).  
AD develops over many decades and a human life is a complex mix of different lifestyle and 
environmental events. Even if these lifestyle factors only have a tiny influence on the 
progression of AD, this could have a substantial additive effect in promoting or delaying the 
progression of the disease over such a long time.  
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2. Amyloid- β peptide 
2.1. Amyloid-β Aggregation 
Aβ, especially Aβ42, is prone to aggregation and forms plaques, a major neuropathological 
hallmark of AD. This aggregation is thought to follow a well-defined pathway to result in 
amyloid fibrils and plaques. It starts with Aβ monomers and they aggregate, via several 
intermediate steps, to form large fibrils with an amyloid structure. Amyloid is defined as “any 
proteinaceous polymer having a β-pleated sheet conformation” (Fiala, 2007).  
The formation of amyloid fibrils from single Aβ peptide molecules is thought to follow a 
sequence of events that, at some stages, is reversible (Bitan et al., 2003; Cruz et al., 1997), 
but eventually becomes a self-propagating mechanism (Figure 6). Aβ monomers can 
reversibly form Aβ oligomers of various sizes and Aβ protofibrils (Grüning et al., 2013; 
Walsh et al., 1999). Protofibrils and oligomers further aggregate to form amyloid fibrils 
(Ahmed et al., 2010), the basic component of plaques (Martins et al., 2008). 
 
 
Figure 6: The Aβ aggregation process. Aβ is released as a monomer. Aβ momomers reversibly 
aggregate to form oligomers and protofibrils. Protofibrils aggregate irreversibly to form amyloid 
fibrils. 
 
The Aβ aggregation process can be artificially accelerated by a process called seeding. Aβ 
may have to reach a certain state of aggregation before plaques can be seeded and by 
artificially providing Aβ in this state, the plaque deposition process is accelerated. This was 
first observed in in vitro experiments of Aβ aggregation. If pre-formed Aβ aggregates are 
added to a solution of Aβ monomers, the solution will form fibrils at a much higher rate than 
a pure Aβ monomer solution (Jarrett & Lansbury, 1992; Lomakin et al., 1997). Moreover, 
injecting brain homogenate from AD patients or aged APP transgenic mice into pre-
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depositing mice produces plaques in these mice much earlier than if they had not been 
injected or had been injected with healthy control or wild-type brain homogenate (Kane et al., 
2000; Meyer-Luehmann et al., 2006). This seeding process is dependent on both incubation 
time and injected material concentration (Harper & Lansbury, 1997; Meyer-Luehmann et al., 
2006). The injected material is thought to contain a seeding factor that induces the 
aggregation of Aβ and the formation of plaques. This seeding factor has yet to be definitively 
identified, but there are some likely candidates. Aβ oligomers could be that ‘seed’ as 
synthetic Aβ oligomers injected into APP transgenic mice were found at the core of new 
plaques (Gaspar et al., 2010), implying the Aβ oligomers were involved in the initiation of 
plaque formation.  
2.2. Amyloid-β Oligomers 
Aβ oligomers may not only seed plaque formation, but may also contribute to neuronal 
toxicity in AD. The amyloid fibrils that make up plaques are large, compact and insoluble 
structures. Smaller, soluble forms of Aβ are thought to be the more likely mediators of 
cellular toxicity in AD (Haass & Selkoe, 2007). Aβ oligomers in particular have been put 
forwards as likely candidates for this toxic role (Larson & Lesné, 2012). 
Aβ oligomers are a diverse group ranging from dimers to dodecamers and larger molecules. 
They have a clear opportunity to exert this toxic function as Aβ oligomers are found both 
intra- and extracellularly. (Benilova et al., 2012). Cell-derived Aβ oligomers, particularly Aβ 
trimers, decreased LTP (long term potentiation) in hippocampal slice culture preparations 
(Townsend et al., 2006) showing that they can perturb key brain functions. Moreover, Aβ 
oligomers derived from human cells and injected into rat ventricles reduced LTP in the 
nearby hippocampus (Walsh et al., 2002) and decreased the rats’ cognitive ability (Cleary et 
al., 2005). A specific Aβ oligomer, Aβ*56, was discovered in older APP transgenic mice that 
disrupted memory when injected into young rats (Lesné et al., 2006) and is lowered in the 
CSF of AD patients (Lesné et al., 2013). Aβ oligomers isolated from AD patients also 
impaired LTP and altered neuronal morphology in hippocampal slice culture (Shankar et al., 
2008) and induced neuritic dystrophies (Jin et al., 2011). In the brains of AD patients, there is 
evidence that Aβ oligomers interact with key synaptic components and oligomer levels are 
correlated to the loss of synaptic proteins (Pham et al., 2010). Taken together, these studies 
strongly implicate Aβ oligomers as a toxic species in AD, although the exact identity of the 
toxic oligomer(s) in question is still under debate. 
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3. The Amyloid Cascade Hypothesis 
The amyloid cascade hypothesis is one of the best hypotheses that we have to model AD 
progression. It was first described by John Hardy and Gerald Higgins in 1992 (Hardy & 
Higgins, 1992). The hypothesis proposed that Aβ is the causative agent in AD and that 
neurofibrillary tangles, cell toxicity and neurodegeneration occur subsequent to Aβ pathology 
(Figure 7). According to the hypothesis, Aβ is the ‘driver’ of a cascade of down-stream 
events that ultimately leads to the death of neurons and the cognitive symptoms of AD. There 
are several lines of evidence to support this and others that cast some doubt on the simplicity 
of the hypothesis. 
 
 
Figure 7: A simplified schematic of the amyloid cascade hypothesis. Aβ overproduction or 
aggregation is the trigger for downstream neuronal events and neurodegeneration in 
Alzheimer’s disease. 
 
In favour of this hypothesis are all the genetically forms of AD identified so far. Forms of 
FAD are very often associated with autosomal dominant mutations that universally implicate 
the production of Aβ in the etiology. There are mutations in APP itself or in the PS subunits 
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of the γ-secretase complex that releases Aβ from APP. These mutations often increase the 
amount of Aβ produced or modify the ratio of Aβ species cleaved from APP (Schellenberg & 
Montine, 2012), supporting the notion that Aβ is the initiator of the disease mechansim. 
Further genetic support for Aβ as the initiator of the cascade is the cognitive deficit and AD-
like pathology seen in Down’s syndrome patients. Down’s syndrome occurs when three 
copies of Chromosome 21 are inherited. The gene for APP lies in Chromosome 21 and so 
Down’s syndrome patients have three copies of the APP gene and produce excess amounts of 
APP. These patients develop Aβ plaques by the age of 40 and subsequent dementia is 
common (Hof et al., 1995; O'Brien & Wong, 2011). This syndrome again implicates APP and 
Aβ as causes of neurodegeneration and dementia. 
Further support for the amyloid cascade hypothesis comes from studies looking at the 
functional effect of Aβ. Aβ, when applied to neuronal cells or slice culture, is toxic to cells 
and detrimental to LTP. A 35 kDa fragment of APP was shown to bind to DR6 (death 
receptor 6) and trigger axonal degeneration and neuronal death (Nikolaev et al., 2009). 
Furthermore, transgenic mouse models expressing FAD mutations in APP and PSEN develop 
AD-like pathology and memory deficits (Hsiao et al., 1996; Radde et al., 2006), implying that 
these proteins do play a causative role in AD.  
Aβ seems to require other proteins, namely Tau, to exert its neurotoxicity. If tau is knocked 
out, Aβ is no longer toxic to neurons and cognitive and behavioural deficits are rescued in a 
mouse model of AD (Roberson et al., 2007). Further evidence implicating Tau, not Aβ as the 
toxic factor in AD is a study correlating neurofibrillary tangle pathology with the neuron loss 
in AD (Giannakopoulos et al., 2003). However, mutations in Tau that increase tau 
aggregation lead to frontal temporal dementia, not AD (Mudher & Lovestone, 2002). 
Therefore, Tau may be the mediator by which Aβ exerts its toxic effect which does not rule 
out Aβ as the initial trigger that starts an independent chain of events leading to AD.  
Critics of the amyloid cascade hypothesis commonly cite the fact that Aβ and plaques are 
found in cognitively normal aged people (Pimplikar, 2009) implying that Aβ and plaques do 
not necessarily spark a cascade of cerebral deterioration and cognitive decline. However, 
these people could simply be in the pre-cognitive phase of AD and their pathology may not 
be advanced enough to show any cognitive decline. Therefore, more in depth study about the 
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pre-cognitive phase of AD is required before this observation could definitively disprove the 
amyloid cascade hypothesis. 
An alternative to the amyloid cascade hypothesis, the presenilin hypothesis of AD proposes 
that loss of PS function leads to the neuropathogenesis of AD (Shen & Kelleher, 2007). This 
hypothesis is supported by the fact that PS knockout mice had a severe loss of cortical 
neurons  and cognitive defects (Saura et al., 2004). Nevertheless, it is still possible for PS 
dysfunction to be caused by Aβ overproduction, since Aβ may be upstream of a cascade that 
leads to a loss of PS function. 
Therapies targeting Aβ plaques and Aβ oligomers have yet to be successful in human trials – 
indeed therapy patients have even declined faster than control patients. For example, in 2010, 
a high profile, stage 3 clinical trial of the γ-secretase inhibitor, Semagacestat, was halted early 
because patients treated with the highest dose of Semagacestat were deteriorating at a faster 
rate than patients treated with placebo (Doody et al., 2013). This failure could be attributed to 
the other, non-APP-shedding functions of γ-secretase or in not treating patients early enough 
in the disease (Karran et al., 2011). A modified version of the amyloid cascade hypothesis 
postulates that Aβ may just be the initial event that triggers a self-propagating cascade of 
adverse brain events that becomes independent of Aβ (Karran et al., 2011). If this is the case, 
then targeting Aβ once the disease has started would have little beneficial effect to the patient 
and this modified hypothesis would have strong implications for future therapeutic 
development.  
A number of clinical studies in the pipeline aiming to slow or halt the progression of AD are 
based on the amyloid cascade hypothesis. A study by the Alzheimer Prevention Initiative will 
treat FAD cases from a Columbian town with a monoclonal antibody against Aβ 
(crenezumab) with the hope of preventing or delaying the certain onset of AD. The 
Dominantly Inherited Alzheimer Network (DIAN) is also running a trial to treat FAD cases 
with monoclonal antibodies against Aβ (gantenerumab and solanezumab) with the hope of 
altering pre-clinical biomarkers and, ultimately, the development of AD. In another study, 
mild to moderate AD patients actively immunised with a fragment of the Aβ peptide 
successfully developed an antibody response, although the efficacy of this strategy in 
improving symptoms has yet to be tested (Winblad et al., 2012). If either of these or other 
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anti-Aβ treatments prove beneficial to AD patients, then this would add strong support to the 
amyloid cascade hypothesis. 
Taken together, this genetic and experimental data does seem to support the amyloid cascade 
hypothesis that Aβ is the primary cause of AD and the amyloid cascade hypothesis remains 
the dominant theory of AD etiology over two decades after it was originally formulated. 
 
4.  Amyloid-β Plaques 
Aβ plaques are one of the two major pathological hallmarks of AD. Plaques are extracellular 
deposits of aggregated Aβ, typically within a spherical region (Fiala, 2007). This thesis 
investigates the growth and development of plaques and this section will examine their role in 
AD.  
4.1. Origin of Amyloid-β Plaques 
The main component of plaques is aggregated Aβ. However, the origin of the Aβ used to 
create plaques and where the aggregation takes places is under debate. There are many 
different hypotheses which are highlighted in the following paragraphs (Figure 8). 
Firstly, there is a theory that Aβ is secreted from blood vessels into the perineuronal space 
where it aggregates and forms amyloid deposits (Figure 8a). This theory is supported by the 
fact that AD patients often display extensive amyloid deposition within the walls of the 
cerebral blood vessels, a phenomenon called cerebral amyloid angiopathy (CAA). CAA is 
frequently associated with intense surrounding plaque pathology in the parenchyma (Kumar-
Singh et al., 2005) showing that cerebral blood vessels and their surroundings are a site for 
Aβ aggregation and a possible source of Aβ. Moreover, cerebral microstrokes in APP 
transgenic mice caused a local spike in plaque number (Garcia-Alloza et al., 2011). An 
intriguing study injected brain homogenate into the peritoneal cavity of APP transgenic mice 
and saw cerebral amyloid deposits predominantly in the vicinity of blood vessels (Eisele et 
al., 2010) showing that Aβ ‘seeds’ may travel in the blood stream and trigger plaque deposits 
to form in the brain. 
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Secondly, there is a theory that neurons secrete Aβ for plaque formation, either from cell 
bodies, or from axon terminals (Figure 8b). A cell culture study discovered that Aβ can be 
released into the extracellular space via exosomes at the cell membrane (Rajendran et al., 
2006). The specific synaptic release of Aβ is supported by data that Aβ levels in the brain 
seem to correlate with local neuronal activity (Bero et al., 2011) and if synaptic transmission 
is blocked, Aβ levels decrease in the parenchyma (Cirrito et al., 2005). Once released in to 
the extracellular space, secreted Aβ could then follow the aggregation pathway to form 
plaques. 
Thirdly, there is a hypothesis that Aβ monomers aggregate intraneuronally to form Aβ 
oligomers or fibrils (Takahashi et al., 2004; Walsh et al., 2000) and are then secreted into the 
extracellular space to induce plaque formation (Figure 8c). Immunohistochemical analysis of 
neuronal cultures showed that Aβ oligomers are found in multivesicular bodies in the 
synapses and along microtubules in neural processes (Takahashi et al., 2004). Further 
validating the idea of intracellular Aβ aggregation, physiological concentrations of Aβ do not 
aggregate to form fibrils in vitro (Parbhu et al., 2002), indicating that other co-factors may be 
needed for aggregation and a study demonstrated that Aβ oligomers were unable to form 
extracellularly and required cells to be produced (Walsh et al., 2000).  
All these theories have considerable experimental support and so it is perhaps probable that 
they all contribute to plaque formation. Aβ originates from many sources and therefore it is 
possible that multiple, diverse mechanisms contribute to the formation of amyloid plaques. 
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Figure 8: Origin of plaques. In (a), Aβ monomers diffuse out of blood vessels into the 
extracellular spaces in the brain, aggregate and deposit as plaques. Alternatively, Aβ monomers 
may originate from neurons, be secreted and thereby form plaques (b). Finally, Aβ could form 
oligomeric aggregates intraneuronally, then be secreted and form plaques (c).  
 
4.2. Diffuse and Dense-cored Plaques 
There are two main types of plaques found in AD: diffuse and dense-cored plaques (Figure 9; 
(Rak et al., 2007)). Diffuse plaques consist of amorphous Aβ (without a β-sheet structure) 
(Tagliavini et al., 1988) and are proposed to be the precursors of dense-cored plaques 
(Armstrong, 1998). Dense-cored plaques are, in contrast, amyloid (β-sheet) rich and are 
typically well stained by amyloid-specific dyes such as Congo Red and Thiaflavin S. Dense-
cored plaques are often surrounded by diffuse Aβ material (Rak et al., 2007). The two parts 
of the plaque – diffuse and dense-core – are very different structures as demonstrated by an 
anti-Aβ antibody therapy study in APP transgenic mice; treatment with the antibody for 12 
weeks stripped the diffuse material from the plaques, but left the dense-core unaltered (Wang 
et al., 2011).  
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Figure 9: The two types of Amyloid plaque. Examples of a dense-cored plaque (a) and a diffuse 
plaque (b) from an 11 month old APP transgenic mouse brain immunostained with anti-Aβ 
antibody 4G8. Adapted from (Rak et al., 2007) 
 
In FAD, the predominant plaque type seems to be determined by the mutation that triggered 
the disease. For example, some forms of FAD with PS1 mutations develop so called ‘cotton 
wool’ plaques (Snider et al., 2005; Steiner et al., 2001; Takao et al., 2002) characterised by 
their large size and limited Thioflavin S staining (Schellenberg & Montine, 2012). Mouse 
models expressing FAD mutations also develop different plaque types based on the 
transgenes they express; APP23 mice develop both Congo Red positive dense-core plaques 
and diffuse plaques (Sturchler-Pierrat et al., 1997) while APPPS1 mice develop mainly 
dense-core plaques (Radde et al., 2006). 
Why these different types of plaque develop and whether the distinctions are important for 
AD progression are still open questions. Understanding more about how the different plaques 
arise may shed some light on the etiology of AD. 
4.3. Amyloid-β Plaque Spreading 
In 1991, a pivotal study of AD patients’ brains obtained at autopsy led to the staging of AD 
severity based on neuropathological changes (Braak & Braak, 1991). Plaque pathology was 
staged based on location and density of deposits and was further refined in a later study (Thal 
et al., 2002). This staging shows that plaques first appear in the neocortex, then in the 
allocortex and diencephalon and finally invade the brain stem and cerebellum (Figure 10). 
This characteristic spatial march of plaque pathology appears to follow the path of 
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anterograde neural connections; once an area displays plaque pathology, the areas 
synaptically connected with that area are subsequently affected (Thal et al., 2002). This has 
lent support to the idea that Aβ pathology is relayed between neurons by synaptic 
connections and spreads throughout the brain along neural networks. 
 
 
Figure 10: Spread of Aβ plaque pathology in AD patients. Plaques first appear in the neocortex, 
then allocortex, then diencephalon and cerebellum. Image adapted from (Jucker & Walker, 
2011). 
 
Synaptic transmission of Aβ is validated by in vitro experiments that showed that neurons in 
culture can directly transfer soluble Aβ from neuron to neuron via direct cellular connections 
(Nath et al., 2012). An electron microscopy study of an AD mouse model showed that Aβ is 
indeed present in synapses and accumulates in vesicles in the pre- and post-synaptic 
compartments of neurons (Takahashi et al., 2002). These data indicate that Aβ is, most likely, 
both released by axonal terminals and taken up by post-synaptic compartments thereby 
travelling along neuronal connections. 
Data obtained from mouse models have also provided support for the spreading hypothesis. 
When APP is expressed exclusively in one region of a mouse brain, the entorhinal cortex, 
plaques are first seen only in this small area, but are later observed in the dentate gyrus, 
specifically at the synaptic terminals of the perforant path that connect the two areas (Harris 
et al., 2010). In the reverse of this study, injection of brain homogenate into the hippocampus 
showed plaque formation in the retrograde entorhinal cortex (Walker et al., 2002). 
Furthermore, severing the axons of the perforant path in APP transgenic mice, reduced 
plaque pathology in the dentate gyrus (Lazarov et al., 2002; Sheng et al., 2002). These studies 
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imply that Aβ is transported bi-directionally along the perforant path to induce pathologic 
changes in the dentate gyrus and entorhinal cortex supporting the notion of Aβ travelling 
through the brain along neuronal connections.  
Taken together, the anatomical and experimental data strongly suggest that Aβ can spread 
intracellularly and trans-synaptically along neuronal connections and, in this manner, plaque 
pathology expands throughout the brain.  
4.4. Amyloid Plaque Toxicity 
Despite being a major pathological hallmark of AD, the amount of plaques in the brains of 
AD patients does not correlate with the severity of the disease symptoms (Terry et al., 1991). 
Therefore, it was thought that plaques could merely be by-products of the AD process, and 
even that they have a protective function in AD (Lee et al., 2004). However, there are several 
hints that plaques may be detrimental to brain tissue, most notably that the cerebral area 
immediately surrounding plaques is differentially disturbed in AD. Synapses are reduced in 
AD (Masliah et al., 2001) and are particularly reduced in the vicinity of plaques (Bittner et 
al., 2012; Spires et al., 2005; Tsai et al., 2004), suggesting that plaques, or some molecules 
associated with plaques, are toxic to neurons.  
Further support for the toxicity of plaques is the morphology of neurites in the vicinity of 
plaques. Neurites normally display very straight trajectory, but near to plaques they appear 
curved and distorted (Knowles et al., 1999; Wu et al., 2010). These distorted neurites often 
have fewer spines. Neighbouring neurites also display signs of oxidative stress in the vicinity 
of plaques (Hensley et al., 1995; McLellan et al., 2003) and antioxidant treatment seems to 
reverse these abnormalities (Garcia-Alloza et al., 2010). This oxidative stress is most likely 
mitigated via mitochondrial damage as mitochondria are less numerous and more fragmented 
in cells nearby plaques (Xie et al., 2013). Moreover, APP transgenic mice treated with anti-
Aβ-antibody to clear plaques showed a marked recovery in plaque-associated neuritic 
dystrophy (Brendza et al., 2005) implying that removing the plaques removed their toxic 
influence on neurites. Neuronal morphological changes also resulted in functional changes, 
since neuronal activity was shown to be decreased near to plaques (Meyer-Luehmann et al., 
2009) and in vivo imaging studies showed that plaques are surrounded by hyperactive 
neurons with more spontaneous firing and higher Ca2+ load which led to altered neuritic 
morphology (Busche et al., 2008; Kuchibhotla et al., 2008). Plaques have also been shown to 
34 
 
exert more long-distant detrimental effects on the brain; inter-hemisphere functional 
connectivity was reduced in areas associated with the degree of plaque deposition in a mouse 
model of AD (Bero et al., 2012).  
An in vivo imaging study in APP transgenic mice revealed a halo of oligomeric Aβ 
surrounding plaques in AD transgenic mice (Koffie et al., 2009). This suggests that perhaps 
the amyloid fibres in plaques are not toxic per se, but that plaques contain soluble Aβ 
oligomers that can diffuse into the surrounding tissue and damage neurons. 
These observations hint that plaques are not mere benign by-products of AD, but their 
presence is detrimental to brain tissue and that they therefore warrant further study. 
 
5. Investigating Amyloid-β Plaques in APP transgenic mice 
This thesis investigates the development of plaques using the APPPS1 transgenic mouse as a 
model of the cerebral amyloidosis seen in AD patients.  
5.1. The APPPS1 Mouse Model  
The APPPS1 mouse model of AD (Radde et al., 2006) expresses two transgenes: human APP 
with the Swedish mutation (Mullan et al., 1992) and human PS1 with the L166P mutation. 
The Swedish APP mutation causes production of Aβ to increase 6-8 fold (Citron et al., 1992) 
due to a different cellular location of β-secretase APP cleavage (Haass et al., 1995). In human 
patients, this leads to FAD with average age of symptom onset 55 and average disease 
duration 7 years (Mullan et al., 1992). The L166P PS1 mutation is very aggressive, with AD 
symptoms beginning in patients as early as 24 years of age (Moehlmann et al., 2002). This PS 
mutation alters the γ-secretase complex to increase the ratio of Aβ40/Aβ42 cleaved from APP 
(Bentahir et al., 2006) and produce mainly the aggregation-prone species Aβ42. 
The APPPS1 mouse develops plaques characteristic of human AD patients. Moreover, the 
plaques develop in a relatively short space of time –they begin to appear in the neocortex at 2 
months of age and by 8 months of age, there is substantial plaque load in these mice (Figure 
11). Plaques are seen in the dentate gyrus at 3 months of age and in the CA1 region by 5 
months of age in female mice. The deposits are over 95% dense cored with plaques in older 
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mice often displaying a diffuse Aβ surround. At 8 months old, APP PS1 mice have 
dystrophic neurites in the vicinity of plaques and show slight neuronal loss. These APP PS1 
mice also develop cognitive deficits: at 8 months of age; they have more difficulty learning a 
maze task than their wild-type littermates (Radde et al., 2006), imitating the loss of spatial 
memory seen in  human AD patients.  
This AD mouse model is ideal to study plaque development over time because this is a rapid 
model with plaques at an early age. These plaques have a very similar molecular structure 
and recapitulate some neuronal and cognitive deficits of AD, which makes it a good model in 
which to study plaque development. 
 
 
Figure 11: Plaque load increases with age in APPPS1 mice. No plaques observed at 1 month of 
age advancing to substantial plaque load at 8 months of age. Anti-Aβ antibody NT12 
immunostaining of the neocortex.  ‘mo’ indicates months of age. Scale bar: 200µm Adapted 
from (Radde et al., 2006) 
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5.2. In vivo 2-photon Imaging in Mouse Models of Alzheimer’s Disease 
This thesis uses acute 2-photon microscopy to image plaque development in APPPS1 mice. 
Conventional assessment of AD brains is carried out on post mortem tissue and only allows 
for a snap-shot/static view of the pathology. With development of 2-photon microscopy and 
cranial window implantation techniques (Holtmaat et al., 2009), the dynamics of cerebral 
pathology in multiple cortical layers of mouse models can be imaged over time, at a far 
greater depth than is possible with confocal microscopy.  
2-photon microscopy uses pulsed infrared light with a long wavelength to prevent light 
scattering at greater depths in the tissue. The fluorophores absorb 2 photons simultaneously, 
instead of the one in conventional microscopy. The 2 photons absorbed each have 
approximately half the energy needed to excite the fluorophore. Because of this dual photon 
mechanism, the area of excitement is much smaller than normal microscopy, therefore 
reducing out of focus excitation and photobleaching.  
Fluorescent dyes such as Methoxy-X04 label amyloid fibres and allow plaques to be 
visualised (Klunk et al., 2002). Methoxy-X04 crosses the blood brain barrier and so can be 
administered peripherally. This means that it can be administered repeatedly which can reveal 
changes in the plaque population over time (Liebscher & Meyer-Luehmann, 2012). Methoxy-
X04 also binds stably to plaques for several months (Condello et al., 2011). Fluorescently-
labelled Pittsburgh compound B (PIB) can also be used to image plaques and binds to 
plaques for up to 3 days (Bacskai et al., 2003). With these staining techniques, combined with 
2-photon microscopy, individual plaques can be followed over time (Hefendehl et al., 2011) 
and the appearance and location of new plaques can be precisely monitored (Meyer-
Luehmann et al., 2008). 
Transgenic technology has been applied to great effect to generate fluorescent-labelled brain 
cells. Green fluorescent protein (GFP) expressing neurons allow for neurites and dendritic 
spines to be visualised with 2-photon microscopy. Studies with labelled neurons have shown 
the temporal relationship between plaques and neuronal abnormalities (Bittner et al., 2012; 
Dong et al., 2010; Meyer-Luehmann et al., 2008) and GFP-labelled microglia were used to 
demonstrate, that microglia can phagocytose Aβ in vivo  (Bolmont et al., 2008). 
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Despite the limited imageable volume and several other technical limitations, 2-photon 
microscopy is a powerful technique. It is an invaluable tool to image the dynamics and 
kinetic of Aβ plaques over time in the same model animal. 
5.3. Growth and Development of Amyloid-β Plaques in Alzheimer’s Disease 
This thesis specifically studies the growth and development of plaques. Plaques are one of the 
major hallmarks of AD and they are accompanied by neuronal and glial changes and 
oxidative stress in the surrounding neuronal tissue. However, little is known about how they 
form and develop over time. Studies in APP transgenic mice have shown that initial plaques 
are quite small, but as the pathology progresses, larger plaques are apparent (Figure 11, 
(Radde et al., 2006)). How these large plaques form is still under debate and is the central 
question of this thesis. An attractive hypothesis that large plaques are simply smaller plaques 
that have grown over time (Figure 12a) has garnered some experimental support (Burgold et 
al., 2011; Condello et al., 2011; Hefendehl et al., 2011). However, an alternative, most likely 
complimentary, hypothesis that small plaques form clusters and fuse together over time to 
give rise to large plaques (Figure 12b), has yet to be thoroughly investigated in vivo. 
  
 
Figure 12: Two Hypotheses of Plaque Development. The uniform growth theory (a) says that an 
initial plaque uniformly grows over time to become a larger plaque. The plaque clustering 
theory (b) says that clusters of plaques form and grow together over time to form a large plaque.  
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A previous study using 2-photon imaging over time in APP transgenic mice showed that new 
plaques can appear very rapidly, within 24 hours. These new-born plaques remained the same 
size for up to two weeks following initial appearance (Meyer-Luehmann et al., 2008). Two 
studies applying 2-photon imaging to AD mice over longer periods have shown that plaques 
grow uniformly over extended periods of time from a single, smaller plaque. The first study 
followed new plaques over 6 weeks in Tg2576 mice and observed a significant increase in 
plaque volume 16 days after the plaque first appeared. Plaque growth was fairly uniform 
throughout the 6 week period, although there was considerable variation (Burgold et al., 
2011). The second study gained very similar results in the APP PS1 mouse model of AD. The 
mice were imaged for up to 6 months and new plaques in this study also showed a uniform 
growth from an initially small plaque (Hefendehl et al., 2011). A study using a very different, 
post mortem ‘time-stamp’ technique also discovered that new plaques are initially small and 
grow gradually over 90 days. This study used Methoxy-X04 to label plaques at one time 
point and then left the mice to develop normally. At various time points afterwards, the mice 
were sacrificed and Methoxy-X04 staining was compared to post mortem staining to denote 
how much the plaques had grown over the intervening time (Condello et al., 2011). Taken 
together, these studies give a picture of plaques that form very rapidly to reach an initial size, 
but then continue to gradually grow uniformly over time. 
Conceivably, this gradual uniform growth is not the only mechanism of plaque growth. 
Analysis of plaque deposition in sections from APP transgenic mice revealed that plaques 
cluster together in small areas. Modelling this with a computer simulation showed that newly 
formed in silico plaques had to form preferentially in the vicinity of a pre-existing plaque to 
create a representative model of in vivo plaque distribution (Urbanc et al., 1999). Plaque 
clustering was also observed in a study of AD patient pathology (Armstrong et al., 1993). The 
clustering hypothesis of plaque growth (Figure 12b) builds on this idea to postulate that these 
clusters of plaques fuse together over time to form single plaques. Furthermore, large plaques 
can be composed of multiple, smaller, precursor plaques. However, detailed in vivo 
experimental evidence is still missing to provide support for this hypothesis. 
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6. Aims of This Study 
By establishing a method to follow plaque development over time, this study thoroughly 
investigated the mechanism and possible mode of plaque development in AD.  
The overall objective of this study was to explore the clustering hypothesis of plaque 
development with three specific aims:  
1) To establish a two-stage staining technique to investigate plaques at multiple time 
points.  
2) To identify the comparative location of new to pre-existing plaques. 
3) To classify and characterise any large plaques that might have formed from clusters 
of pre-existing plaques. 
The successful completion of these aims would provide novel support for the clustering 
mechanism of plaque growth and shed light on the development of a key neuropathological 
hallmark of AD. 
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Materials and Methods 
 
1. Materials  
Standard laboratory materials were purchased from Sigma Aldrich (MO, USA), Merck (NJ, 
USA) or Roth (Germany). Other materials and their manufacturers are listed in Table 1. 
 
Table 1: Non-Standard Materials   
 
Material (trade name) Manufacturer 
6E10 Antibody Sigma Aldrich, MO, USA 
APEXTM AlexaFlor ® 594 Antibody Labelling Kit Invitrogen, CA, USA 
Cremophore EL Sigma Aldrich, MO, USA 
Dental Cement (Paladur) Heraeus, IN, USA 
DNA polymerase (GoTaq®) Promega, WI, USA 
Eye Cream (Bepanthen) Bayer Vital, Germany 
Glue (Pattex Ultra) Henkel, Germany 
Ketamine (Ketavet) Pharmacia, Pfizer, Germany 
Methoxy-X04 Neuroptix, MA, USA 
Mounting Media (Aqua-Polymount) PolySciences, Germany 
PCR reaction buffer (GoTaq®) Promega, WI, USA 
Sterile Sponges (Gelaspon) Cauvin Ankerpharm, Germany 
Thiazin Red Sigma Aldrich, MO, USA 
Xylazine (Rompun) Bayer Vital, Germany 
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2. Equipment  
All laboratory equipment used and their manufacturers are listed below in table 2. 
 
Table 2: Equipment  
 
Equipment (trade name) Manufacturer 
2-photon microscope (FV1000) Olympus, Japan 
Centrifuge (Fresco17) Thermo Scientific, MA, USA 
Drill (Microdrill) Stoelting, IL, USA 
Electrophoresis power supply 
(PowerPac™) 
Bio-Rad, CA, USA 
Fluorescence microscope (BX61) Olympus, Japan 
Metal head bar Custom-made 
Microtome (SM200R) Leica Biosystems, Germany 
Scissors Fine Science Tools, Canada  
Sections slides (Superfrost) Thermo Scientific, MA, USA 
Shaker (KM-2) Edmund Bühler GmbH, Germany 
Syringes (Omnican®) B. Braun, Germany 
Thermocyler (Mastercycler Gradient) Eppendorf, Germany 
Thermoshaker (Thermomixer Compact) Eppendorf, Germany 
Tweezers Fine Science Tools, Canada 
Vortex (Vortex-Genie 2) Scientific Industries, NY, USA 
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3. Buffers  
The buffers used for all experiments are listed below in table 3 along with their composition. 
 
Table 3: Buffers 
 
Buffers Composition 
PBS 14mM NaCl, 10mM Na2HPO4.2H2O, 2mM KH2PO4, 3mM KCl, pH 7.4 
TAE 40mM Tris, 20mM Ascorbic Acid, 1mM EDTA 
Lysis buffer 1M Tris-HCl, 0.5M EDTA, 10% SDS, 2.5M NaCl, 1:1000 Proteinase K 
TBS 600mM Tris,  2.6M NaCl. pH 7.8 
TBST TBS with 0.3% Triton-X 100 
 
 
4. Animals 
Male heterozygous APPPS1 mice expressing human APPKM670/671NL and PS1L166P under the 
control of the neuron-specific Thy-1 promoter (Radde et al., 2006) were used for all analyses. 
Mice were housed in specific pathogen free conditions with a maximum group size of six. 
Mice were kept in a 12/12 hour light/dark cycle and had access to food and water ad libitum. 
All animal procedures were carried out in accordance with animal protocols approved by the 
government of Upper Bavaria, Germany (licence numbers 55.2-1-54-2531.3-13-10 and 55.2-
1-54-2532-152-11). 
4.1. Genotyping 
A small section of tail was removed from each mouse for genotyping. First, the DNA was 
extracted: the tissue was incubated in 500µl lysis buffer overnight at 55°C and agitated at 
750 rpm. 400µl Isopropanol was added and the solution thoroughly vortexed followed by 20 
minutes centrifugation at 17,000 x g. The supernatant was removed and the pellet washed 
with 500µl 70% ethanol. The pellet was air dried and then re-suspended in 150µl distilled 
water and incubated for 5 minutes at room temperature followed by an hour in the 
thermoshaker at 55°C and 750 rpm. 
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The extracted DNA was subjected to a polymerase chain reaction (PCR) to amplify the 
human APP gene - if present. The PCR solution consisted of; 4µl reaction buffer, 0.5µl 
deoxynucleotide triphosphate mix, 1µl forward primer (5’-ATG GAT GTA TTC ATG AAA 
GG-3’), 1µl reverse primer (5’-TTA GGC TTC AGG TTC GTA G-3’), 0.2µl DNA 
polymerase, 11.3µl distilled water and 2 µl DNA. This solution was placed in a thermocycler 
and the following cycle run: 1) 5 minutes at 95°C, 2) 30 seconds at 95°C, 3) 1 minute at 
38°C, 4) 1 minute at 72°C, 5) steps 2) to 4) repeated 30 times, 6) 5 minutes at 72°C and then 
held at 4°C.  
The PCR samples were separated by gel electrophoresis using a 1% agarose TAE gel 
containing 1:2500 ethyl bromide using TAE buffer as the running buffer. 90V of voltage was 
applied for approximately 20 minutes and the gel imaged with a UV light source. A 
photograph was taken for documentation. 
4.2. Two-Stage Staining Technique 
Cerebral plaques were stained pre mortem with Methoxy-X04 on day 0 of the experiment to 
label all plaques at that time (Figure 13a). After an incubation time of 1 day, 1 month or 4 
months, one of two protocols were carried out (Figure 13 b). Either an anti-Aβ antibody was 
topically applied to the brain, followed by acute in vivo imaging, or, the mouse was sacrificed 
for post mortem Aβ staining. The number of mice in each group is listed in table 4. 
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Figure 13: Schematic of dual staining technique. First, the mouse is injected with Methoxy-X04 
(a). After 1day, 1 month or 4 months, the mouse was either imaged in vivo, or sacrificed for post 
mortem analysis (b). 
 
 
Table 4: The Number of Animals Used in Each Experimental Group. 
 
Group name Age of animal at 
Methoxy-X04 injection 
Post injection 
interval 
Number of 
animals 
Early 2 months 2 weeks 4 
1 Day 3 months 1 day 5 
1 Month 3 months 1 month 6 
4 Months 3 months 4 months 5 
Acute in vivo imaging 3 months 4 months 3 
 
4.3. Pre Mortem Amyloid-β Plaque Staining 
Methoxy-X04 was injected intraperitoneally into 2 or 3 months old mice (apart from one 
group of mice that were injected at 2 months of age – see table 4). The Methoxy-XO4 
solution consisted of 33.3% 10mg/ml Methoxy-X04 in DMSO and 66.6% volume 
Cremophore EL in PBS and was applied at a dose of 3.33 µg/kg body weight. 
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5. Acute In Vivo Imaging 
5.1. Antibody Labelling 
To directly image an antibody applied directly to the surface of the brain without the need for 
a secondary antibody, the anti-Aβ antibody 6E10 was covalently bound to the fluorophore 
Alexa 594. To label the antibody, an antibody labelling kit was used according to the 
manufacturer’s instructions. Briefly, the provided column was hydrated and the 6E10 
antibody and dye mix applied to the column. The column was incubated at room temperature 
for 2 hours and then washed twice before the labelled antibody was eluted with neutralisation 
buffer. The labelled antibody was stored at 4°C until further use. 
5.2. Cranial Window Implantation 
Mice were anaesthetised with a mixture of Ketamine (10 µg/kg) and Xylacine (20 µg/kg) 
administered intraperitoneally. The eyes were covered with eye cream to prevent harm. The 
fur was sterilised with ethanol and a circular piece of skin removed from the top of the head 
with small scissors. The skull was cleaned with cotton buds and a circle, approximately 6 mm 
in diameter, lightly drilled into the bone with a micro drill. The anterior of the circle was 
approximately 1 µm above bregma, the posterior of the circle just above lambda and the 
circle was equally positioned over the parietal cortex of both hemispheres. Using the tip of a 
syringe, the skull outside the circle was treated to create a mesh of light scratches to give the 
glue a rougher surface to adhere to. The circle was drilled more deeply until tweezers could 
be inserted under the bottom of the circle and the entire circle of bone easily removed. Small 
pieces of sterile PBS-soaked sponges were gently placed on top of the exposed dura mater to 
absorb any blood. 
Once the bleeding had stopped, the dura mater was removed from the visible brain with fine 
tweezers. Sponges were applied again to absorb any blood. Once the bleeding had stopped, 
20 µl of Alexa 594-labelled 6E10 was applied to the cerebral cortex for 30 minutes. Plastic 
film was used to keep the antibody in place and prevent evaporation and the mouse’s head 
was covered in aluminium foil to avoid fluorophore bleaching. After 30 minutes, the antibody 
was removed and the brain surface washed 2 x 30 minutes with sterile PBS. The head was 
also covered with foil during these washing steps. An 8 mm circle of glass was placed on top 
of the exposed brain. Any excess liquid was removed from underneath the glass with small, 
absorbent sponges. Glue was applied between glass and the bone surrounding the exposed 
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brain. Care was taken that no glue leaked onto the brain itself. Once the glue was dry, a raised 
circle of dental cement was applied to fix the window in place and to create a well to contain 
the microscope objective immersion water. A small metal head bar with two holes drilled in 
was placed into the cement to attach the mouse to the microscope apparatus. 
5.3. In vivo 2-photon Microscopy 
The mouse was secured, using the head bar, in a custom-built frame with three-dimensional 
adjustability. The frame was positioned under the 2-photon microscope. Surface blood 
vessels were imaged with the fluorescence lamp and used for gross orientation.  
The Mai Tai Deep See Laser (Spectra Physics, Newport Corporation, MA, USA) at 850 nm 
was used to excite the two dyes. A 420-500 nm emission filter was used to image the pre-
mortem injected Methoxy-XO4 and a 590-650 nm emission filter used to image the topically 
applied Alexa 594-labelled 6E10 antibody. 634 x 634 x 150 µm (xyz dimensions) volumes of 
cortex were imaged with a resolution of 512 x 512 pixels and 5µm z axis increments. Images 
were collected and processed using the Olympus FV10-ASW 3.1 software. 
 
6. Post Mortem Imaging 
6.1. Section Preparation 
The mice were sacrificed and the brains removed. The brains were fixed in 4% PFA for 
48 hours followed by 48 hour in 30% sucrose in PBS. The tissue was then flash frozen on dry 
ice and stored at -20°C until further use. Brains were sliced into 25 µm thick sections with a 
microtome cooled with dry ice. Sections were collected in 10 1.5 ml centrifuge tubes so that 
each tube contained every 10th section. Sections were stored in a solution of 15% glycerol in 
PBS at -20°C until further use.  
6.2. Antibody Staining 
Sections were washed 3 x 10 minutes in TBS to remove any glycerol and blocked in a 
solution of 5% NGS (normal goat serum) in TBST for 60 minutes.  This was carried out at 
room temperature and sections were gently agitated on a shaker during incubation steps. The 
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sections were incubated overnight at 4°C with gentle agitation in primary antibody (see table 
5) diluted in 5% NGS in TBST.  
 
Table 5: Primary Antibodies Used for Section Staining 
 
Antibody Antibody Conditions Manufacturer 
3552 1:3000, overnight, 4°C Non-commercial (Page et al., 2010) 
4G8 1:150, overnight, 4°C Covance, NJ, USA 
 
The primary antibody was removed and the sections washed 3 x 10 minute with TBST. The 
sections were incubated in secondary antibody (see table 6) diluted in 5% NGS in TBST for 
one hour. This was followed by 3 x 10 minute TBST washes and a final, 10 minute wash in 
TBS.  
 
Table 6: Secondary Antibodies Used for Section Staining 
 
  Antibody Antibody Conditions Manufacturer 
Alexa 488 1:1000, 1 hour, room temperature Invitrogen, Life Technologies, UK 
Alexa 555 1:250, 1 hour, room temperature Invitrogen, Life Technologies, UK 
 
6.3. Thiazin Red Staining 
Sections were thawed and washed 3 x 10 minutes in PBS to clean the sections of any 
glycerol. Sections were incubated for 20 minutes in a 2 µM solution of Thiazin Red diluted in 
PBS. The sections were then washed 3 x 5 minutes in PBS. 
6.4. Section Mounting 
The stained sections were mounted onto coated glass slides, dried and covered with mounting 
media and a glass coverslip. 
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6.5. Post Mortem Microscopy 
Mounted sections were imaged with a multi-channel fluorescent microscope with an EXFO-
Xcite Laser. A 20x UPLSAPO air objective was used. The filters used for each dye are listed 
in Table 7. 
 
Table 7: Fluorescence Filters used for Imaging 
Dye Filter Excitation (nm) Emission (nm) 
Methoxy-X04 U-MNUA 345 455 
Alexa 488 U-MNIBA  495 519 
Alexa 555/Thiazin Red  Cy3 filter 550 565 
 
Images were taken using an F-view 11FW camera (Olympus) and were 688 x 512 µm in size. 
Images were taken of the dorsal, lateral and ventral cortical regions of both hemispheres. 
Each image was defined as a region of interest (ROI). Therefore 6 ROIs were imaged per 
brain section. This resulted in a total of 89 ± 10.3 (mean ± standard deviation) ROIs imaged 
per animal. 
6.6. Post mortem Methoxy-X04 Staining 
Sections were thawed and washed 3 x 10 minutes in PBS to clean the sections of any 
glycerol. Sections were mounted and covered as above and images of the pre-mortem 
Methoxy-X04 were taken as above. Slides were soaked in distilled water for 2 to 3 minutes to 
remove the cover slip. Care was taken not to dislodge any mounted sections. The slides were 
incubated for 10 minutes in a 100 µM solution of Methoxy-X04 diluted in 40% ethanol, 
pH 10 and then briefly dipped in distilled water five times. The slides were then incubated in 
a solution of 0.2% NaOH in 80% ethanol for 2 minutes and then washed in water for 
10 minutes. A coverslip was attached with mounting media and the section re-imaged at the 
same locations as the pre mortem Methoxy-X04 images. 
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7. Image Analysis 
Images were analysed using Photoshop CS5 (Adobe Systems Inc. CA, USA). Background 
signal was manually subtracted using the linear histogram tool. Pre and post mortem plaque 
staining were compared with each other and a new plaque defined as any structure positive 
for post mortem dye, but Methoxy-X04 negative.  The distance between plaque cores was 
measured in ImageJ (National Institute of Health freeware). New plaques < 40 µm from a 
pre-existing plaque as measured from core to core were categorised as close or ‘in the 
vicinity’ of the pre-existing plaque.  
Flower plaques were defined as a cluster of plaques with two or more new plaques in the 
vicinity (< 40 µm) of a common pre-existing plaque. They were called ‘flower plaques’ due 
to their resemblance to petals around a central core. Multicore plaques were defined as 
plaques that were a single structure in the post mortem staining, but had two or more distinct 
Methoxy-X04 cores. All the plaque categories are summarised in Table 8. 
 
Table 8: Description of Plaque Categories 
Plaque Category  Description 
Pre-existing  Methoxy-X04 and anti-Aβ antibody positive 
New Methoxy-X04 negative, anti-Aβ antibody positive 
New in vicinity A ‘new’ plaque < 40 µm from a ‘pre-existing’ plaque 
Flower ≥ 2 ‘new’ plaques < 40 µm from the same ‘pre-existing’ plaque 
Multicore ≥  2 distinct Methoxy-X04 positive cores within a single antibody 
positive plaque 
 
Plaque size distribution was computed in ImageJ. Smoothing, thresholding and background 
subtraction steps were carried out before an ‘analyse particles’ command was run. The lower 
size limit for a plaque was set as ≥ 30 pixels (≥ 5.5 µm2) of anti-Aβ antibody positive area. 
Autofluorescent signal from particles or section edges was manually removed from the data 
set. 
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To mimic a chance level of plaque deposition in close vicinity of a pre-existing plaque,  a 
rotation analysis was performed  (Keck et al., 2011). A mask containing marks for the 
location of newly developed plaques was rotated by 180° and superimposed onto the pre-
existing plaque image. The distance between these rotated ‘new plaques’ and original pre-
existing plaques was measured and the proportion of new close plaques (< 40 µm) occurring 
by chance was compared to the original fraction of new plaques. 
To quantify the areal fraction of each ROI that was in the vicinity (< 40 µm) of a new plaque, 
ImageJ software was used to superimpose circles with a radius of 40 µm centred over every 
new plaque. The software was used to combine any overlapping circles and quantified the 
area covered by the combined circles. The proportion of ROI covered by the circle area was 
calculated gave me the fraction of ROI area within 40 µm of a new plaque.  
 
8. Graphs and Statistics 
Data was collected in Microsoft excel and graphics generated with GraphPad prism 5.04. All 
data was tested for normality with the D’Agostino-Pearson omnibus K2 normality test with 
the significance level set to p < 0.05. The appropriate parametric or non-parametric test was 
then carried out in GraphPad prism 5.04.  
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Results 
 
1. Two-stage post mortem imaging technique  
To follow the single plaques over their development, a two-stage staining technique was 
developed that allowed for two snap-shots of the plaque development to be imaged 
simultaneously. Methoxy-X04 was injected intraperitoneally at Day 0 to label the plaques at 
this time point. Methoxy-X04 crosses the blood-brain-barrier, stably binds to dense core 
plaques and remains bound and fluorescent for several months (Condello et al., 2011). 
Following a subsequent post-injection time of 1 day, 1 month or 4 months, an anti-Aβ 
antibody was applied to post mortem sections to label the plaques in their current state. Thus, 
how the plaque looked at day 0 was labelled with Methoxy-X04 and how it looked, e.g. after 
4 months was labelled with the anti-Aβ antibody. Comparing the two stainings made new 
plaques and changes to plaques in the period between the two label applications visible 
(Figure 14). It is important to note that the longer incubation time also equates to older 
animals.  
 
 
Figure 14: Example of dual staining. The core of the plaque is stained with Methoxy-X04 
(green) and the Aβ antibody (red) stains the diffuse surrounding as well as the dense core. 
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The vast majoriy, 96.2%, of all plaques counted were double stained after 1 day with only a 
negliable amount of Methoxy-X04-negative plaques. This confirms an earlier study of this 
mouse model which showed that these mice almost exclusively develop dense core plaques 
(Radde et al., 2006) 
The post mortem anti-Aβ antibody 3552 applied to sections (Figure 15) after 1 day (Figure 
15 a-c), 1 month (Figure 15 d-f) and 4 months (Figure 15 g-i) after Methoxy-X04 injection at 
day 0 revealed that after 1 day of incubation, almost all plaques were double labelled (Figure 
15 c). However, after 1 and 4 months,  some new plaques in the anti-Aβ antibody staining 
were clearly identifiable due to their lack of Methoxy-X04 staining (white arrow heads, 
Figure 15 f, i). Additionally, some new plaques appeared very close to pre-existing plaques 
(< 40 µm, yellow arrow heads, Figure 15 f, i). 
 
Figure 15: Two-stage staining technique allows for new plaques to be distinguished from pre-
existing plaques. Methoxy-X04 (MX) was applied at day 0 (a, d, g) and post mortem anti-Aβ 
antibody 3552 (Aβ) applied 1 day (b), 1 month (e) or 4 months (h) after day 0. After 1 day, 
almost all plaques were double-stained (c). After 1 month (f) or 4 months (i), new plaques 
(white arrow heads) and close new plaques (yellow arrowheads) could be distinguished by 
comparing the two stainings. Scale bar: 100 µm 
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To further characterise the end point of the three incubation time groups, the size of all the 
anti-Aβ antibody positive plaques at the three time points were quantified (Figure 16). The 
plaques were separated by size into small (< 50 µm2), medium (50-300µm2) and large 
(> 300µm2) plaques. There were more plaques in general in the longer incubation time groups 
and, notably, many more medium and large plaques. 
 
                          
 
Figure 16: Size distribution of plaques. The number of plaques increases with increasing 
incubation time in all 3 categories of plaque size – small (< 50 µm2), medium (50-300 µm2) and 
large (> 300 µm2) plaques. Mean ± SEM. n = 5-6 per group. 
 
2. Two-stage in vivo Imaging  
Acute 2-photon in vivo imaging also used a two-stage staining technique to visualise new 
plaques.  An anti-Aβ antibody was applied directly to the brain surface of a mouse that had 
received Methoxy-X04 4 months earlier.  A cranial window was then implanted and the 
cerebral cortex of the anaesthetized mouse was imaged.  New plaques that were just antibody 
stained could be distinguished from pre-existing plaques (Figure 17 c, white arrowheads 
point to new plaques). However, as this technique has a very low penetrance of the antibody 
(~200 µm deep into the tissue) and the volume of tissue that can be analysed is much smaller 
than post mortem preparation (Spires et al., 2005), this study investigated plaque 
development primarily with post mortem tissue analysis. 
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Figure 17: In vivo 2 photon imaging of new plaques 4 months after Methoxy-X04 injection. 
Methoxy-X04 (MX) was applied 4 months before imaging session (a) and Alexa 594 labelled 
anti-Aβ antibody 6E10 (Aβ, b) topically to the brain before cranial window attachment. The 
merged image (c) allows for newly formed plaques (white arrowheads) to be distinguished from 
pre-existing plaques. Scale bar: 50 µm. 
 
3. Detailed Images of Plaque Categories 
High magnification images of double-stained plaques allowed for a more detailed view of the 
two-staining technique. If plaques were stained with both Methoxy-X04 and anti-Aβ 
antibody 3552, then they were categorised as pre-existing plaques, but plaques without 
Methoxy-X04 staining must have developed over the incubation time and are therefore new 
plaques. New plaques could be identified very close (< 40 µm) to pre-existing plaques after 
all time points investigated (Figure 18, yellow arrowheads in c, f, i). 
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Figure 18: High magnification images of close new plaques. Comparison of the Methoxy-X04 
staining (MX, a, d, g) and the anti-Aβ antibody 3552 (Aβ, b, e, h) showed close new plaques 
(yellow arrowheads) 1 day, (c), 1 month (f) and 4 months (i) after Methoxy-X04 injection. Scale 
bar: 25 µm 
 
4. Staining Validation 
To ensure that the 3552 anti-Aβ antibody staining was representative of Aβ, a second slightly 
different Aβ antibody, 4G8 was used and compared with the 3552 antibody. 4G8 was chosen 
for comparison due to its frequent use in AD patient data and it was shown to be the best 
antibody at labelling diffuse amyloid in human sections (Alafuzoff et al., 2008). The 4G8 
plaque staining (Figure 19) compared very well with the 3552 staining. For example, the 4G8 
antibody stained plaques at 3 time points (Figure 19 d, h, l),  are very comparable to those 
seen with the 3552 anti-Aβ antibody, especially the appearance of the staining and the size of 
the antibody halo around the Methoxy-X04 positive core (Figure 18 c, f, i). Comparing the 
4G8 staining to Thiazin Red  (a post-mortem dye for dense core plaques) (Bacskai et al., 
2003) confirmed that 4G8 stains not only the dense core of the plaque, but also the diffuse 
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surround. This confirms the reliability of the 3552 anti-Aβ antibody as it compares 
favourably to another, well used, anti-Aβ antibody. 
 
 
Figure 19: Staining with another anti-Aβ antibody, 4G8, showed staining of surrounding plaque 
halo 1 day (a-d), 1 month (e-h) and 4 months (i-l) after Methoxy-X04 injection. Thiazin Red 
(TR) shown for comparison (b, f, j). The plaque halo increased with increasing post injection 
time (d, h, l). Scale bar: 50 µm 
 
To ensure that the ‘new’ plaques detected had genuinely appeared after the initial Methoxy-
X04 injection and were not simply a different category of plaque,  some sections were re-
stained with Methoxy-X04 post mortem. This involved imaging the slices with their pre-
mortem Methoxy-X04 staining, removing the cover slip and re-staining the slice with 
Methoxy-X04. The slice was then re-imaged and this image was manually overlaid onto the 
previous image of the initial Methoxy-X04 staining. The two images were then compared to 
find newly appeared plaques that were present in the overlay, but not in the original image. 
57 
 
New plaques were identified that were not visible with the Methoxy-X04 injected at Day 0, 
but were visible in the post-mortem Methoxy-X04 applied 4 months after injection (white 
arrowheads, Figure 20 c), confirming that newly appeared plaques can be Methoxy-X04 
positive and therefore have the same structural characteristics as the pre-existing plaques.  
Similar results were obtained with post mortem Thiazin Red staining.  Sections were taken 
from an animal that had Methoxy-X04 4 months prior to sacrifice and were stained with 
Thiazin Red. This Thiazin Red staining also confirmed the dense core nature of new plaques 
as plaques were visible in the Thiazin Red channel that were not seen in the Methoxy-X04 
channel (white arrow heads, Figure 20 f). Analysis of Thiazin Red staining compared to the 
anti-Aβ antibody 3552 affirmed that only 0.8% of plaques were not dense core positive, 
further validating the antibody staining technique. 
 
 
Figure 20: Post mortem dense core staining. (a-c) Comparison between pre-mortem Day 0 and 
(b) post mortem 4 months Methoxy-X04 (MX) staining showed that new plaques were 
Methoxy-X04 positive (white arrowheads, c). (d-f) Post mortem 4 months Thiazin Red (TR) 
staining (e) compared to pre-mortem Day 0 Methoxy-X04 (d) also revealed new dense core 
plaques (white arrowhead, f). Scale bar: 25 µm 
 
In this study, the Methoxy-X04 is in the brain for up to 4 months and could well be degraded 
over that time. Although Methoxy-X04 has been shown to be stable in vivo over long periods 
58 
 
(Condello et al., 2011), it was important to ensure that Methoxy-X04 did not fade over time 
in this experiment, under these particular conditions. If Methoxy-X04 did fade, then there is 
the possibility that the Methoxy-X04 staining could be lost over time and that plaques that 
were classified as new due to their lack of Methoxy-X04 could therefore not really be new, 
but pre-existing plaques that have lost their Methoxy-X04 staining. If this happens, then a 
decrease in Methoxy-X04 positive plaques over time would be expected as the dye faded. 
However, quantification of the amount of Methoxy-X04 in the different time points, did not 
reveal a decline, but rather even a slight, but non-significant, increase in the amount of 
positive plaques over time (Figure 21). These data indicate that plaques did not lose their 
Methoxy-X04 staining over the 4 months of this study. 
 
 
Figure 21: Percentage of ROI Methoxy-X04 positive. The proportion of ROI covered with 
Methoxy-X04 positive signal increased with increasing incubation time, but not significantly. 
Mean ± SEM, n = 5-6 per group. Kruskal-Wallis with Dunn’s post hoc test. n.s. p>0.05.  
 
5. Investigation of New Plaques 
To quantify how the new plaques had developed over time, all plaques were classified into 
new and pre-existing plaques. To study where the new plaques formed, the new plaque 
category was further sub-divided and the distance between new plaques and their closest pre-
existing neighbour determined the categorisation. The two groups were < 40 µm and > 40 µm 
from a pre-existing plaque. For each ROI, the number of plaques belonging to each of the 
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three plaque categories were quantified (Figure 22 a). This quantification showed that the 
total amount of plaques goes up with increasing incubation time (as would be expected – 
these mice are also older) and that the amount of new and close (< 40 µm) new plaques also 
increases. The proportion of new plaques that were found in the close vicinity of a pre-
existing plaque was, however, consistent over all incubation times; around 22% of all new 
plaques were found in the vicinity of a pre-existing plaque, regardless of incubation time 
(Figure 22 b).  
 
 
Figure 22: Proportion of plaques by classification. (a) Number of total plaques, new plaques and 
close new plaques increased with increasing incubation time. Mean ± SEM, n = 5-6 per group. 
(b) The proportion of the new plaque population that was close to a pre-existing plaque was 
fairly constant across all 3 incubation times. Mean ± SEM, n = 5-6 per group. 
 
Next, the close (< 40 µm from a pre-existing plaque) new plaque population was explored in 
more detail. Was it just chance that this 22% of all new plaques occurred in the vicinity 
(< 40 µm) of a pre-existing plaque? Did the plaques randomly deposit there, or was the 
vicinity of a plaque more conducive than other areas of the brain for a new plaque to form? 
To answer these questions, the original data set was compared to a set of data generated to 
represent the chance deposition of plaques.  
To generate the chance data set,  the location of the new plaques were marked on an overlay 
of the original image, rotated this overlay by 180° and then measured the distance of these 
rotated ‘plaques’ on the overlay and the nearest pre-existing plaque on the original image. 
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This ‘rotated 180°’ data set had a significantly lower average of new plaques close (< 40 µm) 
to a pre-existing plaque than the original dataset, but only in the younger animals group 
(Figure 23 a); the younger animals group is made up by combining the early and 1 day 
groups (see Table 4 for details.). This implies that in the original dataset, plaques formed 
close to pre-existing plaque at a higher than chance level thereby forming clusters of multiple 
plaques. However, in the longer incubation (1 and 4 months) time points, there was no 
difference between the original and ‘chance’ rotated 180° data sets (Figure 23 b).  
 
 
Figure 23: Likelihood of plaque appearing in the vicinity of a pre-existing plaque. Close new 
plaques in original and chance data sets. Y axes display the % of new plaques that are in the 
vicinity of a pre-existing plaque. (a) Likelihood of plaque appearing in the vicinity (< 40 µm) of 
pre-existing plaque is higher than chance (represented by the rotated 180° data set) in younger 
animals. (b) In the 1 month and 4 month incubation time points, the likelihood was no higher 
than chance. Mean ± SEM, n = 5-8 per group. Symbols represent individual animals. Two-tailed 
paired T-test. * p< 0.05, n.s. p> 0.05. 
 
This apparent discrepancy between incubation time groups could be due to the increase in 
plaque density over time (Figure 24 a). As the incubation time increased, the pathology 
worsened and the plaque load increased. There was a negative correlation between the 
number of plaques per regions of interest (ROI) and the difference in the original and rotated 
180° data sets (Figure 24 b). With a lower plaque density, the difference was positive – 
implying that the original data was more than chance, but at a higher number of plaques/ROI, 
the difference was gone – implying that the original data was no more than chance level and 
the likelihood of a new plaque appearing close to a pre-existing plaque was no more than 
chance level.  
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The high density of plaques at longer incubation times indicates that the proportion of ROI 
area < 40 µm from a new plaque is quite large. This was quantified by laying circles with a 
radius of 40 µm on top of all new plaques and determining what proportion of the ROI was 
obscured by these circles (Figure 24 c). The proportion of a ROI < 40 µm from a new plaque 
was dramatically larger in the longer incubation times leading to an increased chance of 
randomly being close to a pre-existing plaque. 
 
 
Figure 24: Plaque density over time. Longer incubation time increased the number of plaques 
per ROI (a). Mean ± SEM. n = 5-6 per group. The graph in (b) shows the difference between the 
original and rotated values plotted against the total numbers of plaques per ROI for each animal 
as determined by Aβ antibody staining. A value of zero indicates that the original and rotated 
values were the same and therefore chance level. n=20, various ages and incubation times; 
negative linear regression (R2=0.4915) line significantly different from zero (F test, p = 0.0006). 
Graph (c) shows the proportion of ROI area that was < 40 µm from a new plaque. Mean ± SEM. 
n = 5-6 per group. 
 
Some very close new plaques cluster around the same pre-existing plaque – this constellation 
was named a ‘flower plaque’ due to their resemblance to petals around a common central 
plaque (Figure 25).  Flower plaques were defined as any Methoxy-X04 positive plaque with 
≥ 2 new plaques < 40 µm away. Acute in vivo imaging first revealed a flower plaque (Figure 
25 a-c) as shown by the new plaques (yellow arrowheads) clustered around a common 
Methoxy-X04 positive plaque. In the post-mortem 3552 anti-Aβ antibody analysis, several 
flower plaques were found with an example shown in Figure 25 d-f, yellow arrowheads point 
to new, ‘petal’ plaques. A quantification of the post mortem analysis revealed that 10.5% of 
all close new plaques contribute to flower plaque clusters (Figure 25 j). Post mortem Thiazin 
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red staining showed that the flower plaque petals can also be of dense core nature (Figure 25 
g-i). These flower plaques are examples of plaques forming a cluster of multiple plaques. 
 
              
 
Figure 25: Multiple new plaques cluster around pre-existing plaque to form ‘flower plaques’. 
(a-c) Flower plaques were seen during in vivo imaging and distinguished by multiple new 
plaques around a pre-existing Methoxy-X04 (MX) positive core (yellow arrowheads in c). (d-f) 
Post mortem analysis also revealed flower plaques with anti-Aβ antibody 3552 (Aβ) and in (g-i) 
with Thiazin Red (TR) staining. White arrow heads point to new plaques > 40µm from the pre-
existing plaque. (j) Quantification of post mortem anti-Aβ antibody flower plaques showed that 
10.5% of all close new plaques were petals of a flower plaque. Scale bars: 25 µm 
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To determine whether there was any particular ‘preferred’ distance for the close new plaques 
within this 40 µm range, the exact distances between the close new plaques and their nearest 
pre-existing neighbour was measured. Figure 26 shows the results of this analysis for each of 
the 3 incubation time points. The 1 and 4 month time points have a small proportion of very 
close plaques (closer than 15 µm from nearest pre-existing plaque), but a plateau at the 
farther distances. In contrast, the 1 day time point had most close plaques within 15 µm and a 
smaller proportion at further distances (20 – 40 µm). Therefore there did not appear to be any 
preferred distance for the close new plaques, but the discrepancy between the 1 day and the 
two later time points may be a technical artefact which will be discussed later. 
 
 
Figure 26: Distance of new plaques from nearest pre-existing plaque. Data plotted for three 
incubation times: 1 day, 1 month and 4 months. Mean ± SEM. n = 5-6 per group. 
 
6. Multicored Plaques Show Merger of Plaques over Time 
Detailed analysis of high resolution pictures revealed an interesting class of plaques that were 
named ‘multicore plaques’. These plaques are characterised by multiple, separate 
Methoxy-X04 cores within a larger plaque stained with the anti-Aβ antibody 3552 (Figure 
27). Multicore plaques were evident after just 1 day (Figure 27 a-c) as well as in the 1 month 
(Figure 27 d-e) and 4 months (Figure 27 g-i) incubation time. This characteristic staining 
strongly implies that these plaques were originally two separate plaques (in the Methoxy-X04 
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staining), but then merged over time to ultimately form one, larger plaque (in the anti-Aβ 
antibody staining).  
 
 
Figure 27: Large, multicored plaques formed from multiple pre-existing plaques. Multicored 
plaques have more than one Methoxy-X04 (MX) positive core (a, d, g) within a single anti-Aβ 
antibody 3552 (Aβ) positive area (b, e, h). Multicored plaques were found after 1 day (c), 1 
month (f) and 4 months (i) of incubation time. Scale bar: 25 µm. 
 
The occurrence of these multicored plaques were quantified and the number of multicored 
plaques increased significantly with increasing post-Methoxy-X04-injection incubation time 
(Figure 28 a), showing that multicored plaques were more numerous with more advanced 
pathology. The size of multicored plaques was also examined and, interestingly, the size of 
multicored plaques was correlated with the number of cores the multicored plaque contained 
(Figure 28 b); a larger multicore plaque had more precursor plaques. Multicore plaques 
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appear to be a very consistent phenomenon as they contribute ~13% of all large (>300 µm2) 
plaques, regardless of incubation time (Figure 28 c). 
 
 
Figure 28: Multicored plaques. The number of multicored plaques per ROI increases with 
incubation time (a). Mean ± SEM. n = 5-6 per group. Kruskal-Wallis test with Dunn’s post hoc 
text. * p<0.05. The number of cores per multicored plaque is positively correlated to the size of 
the plaque (b). Linear regression, R2=0.07474; p<0.0001, n=687 plaques from 5 mice. The 
proportion of large (>300µm2) plaques that were multicored plaques was fairly constant over 
incubation time (c). Mean ± SEM. n = 5-6 per group. 
 
To examine the fate of the cores of these multicored plaques, brain sections were stained with 
Thiazin Red, a post mortem stain for dense-cored plaques. Thus, the core at day 0 was stained 
with Methoxy-X04, but how the dense material looked at the end of the incubation time was 
shown with the Thiazin Red staining. A triple staining method allowed for the initial dense 
core state to be labelled with Methoxy-X04, the ultimate dense core state to be labelled with 
Thiazin Red and the ultimate diffuse state labelled with anti-Aβ antibody 3552 (Figure 29).  
Comparison of these three stainings revealed two fates for the dense cores of multicored 
plaques as defined by multiple Methoxy-X04 positive cores within an anti-Aβ antibody 
positive plaque. Firstly, the multiple cores can merge together over time to create a single, 
dense cored plaque (Figure 29 e-h), showing that dense core material can fuse over time. 
Secondly, the multiple cores can remain separate within the antibody labelled material  
Figure 29 a-d), despite the cores being very close together. Approximately 25%  
Figure 29 i) of all multicored plaques cores fused over the 4 month incubation period. The 
rest, 75%, still had multiple Thiazin Red positive cores, showing that they had remained 
multicored over this period. These data show that dense cores can merge over time. 
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Figure 29: Fate of multicored plaques. Thiazin Red (TR) post mortem staining was used to 
examine the fate of multicore plaques defined by their multiple Methoxy-X04 (MX) cores. In 
(a-d), the cores remain separate (white arrows) within the anti-Aβ antibody 3552 (Aβ) staining 
and the plaque is still multicored at the 4 month time point. In (e-h) the two MX cores have 
merged into one TR core by the 4 month time point (white arrows). (i) Proportion of multicored 
plaques that merge or remain multicored over 4 months incubation time. n=5. Scale bar: 25 µm. 
 
When these triple stained images were examined for examples of newly emerging multicored 
plaques, plaques were found that would not be classified as multicored from the Methoxy-
X04, day 0 staining, but that would be 4 month later  by the Thiazin Red staining (Figure 30). 
These plaques had developed into multicore plaques over the 4 month incubation time 
showing that a new close plaque had developed over the 4 months. This phenomenon 
demonstrates that the multiple dense cores of multicored plaques can form sequentially. 
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Figure 30: Multicored plaques can form at different times. A single plaque (a) is joined by a 
newly formed dense cored plaque (b, white arrowhead) within the anti-Aβ antibody positive 
halo (c, d). Scale bar: 25 µm. 
 
This study has identified three interesting plaque categories of plaques: flower plaques, 
clusters of plaques and merging plaques. In a control experiment, the post-mortem Methoxy-
X04 images were re-examined to find examples of these categories to rule out any 
confounding effect of the multiple staining techniques. Indeed, examples of all three plaque 
categories could be found in these images: flower plaques (Figure 31a), plaque clusters 
(Figure 31b) and merging plaques (Figure 31c). 
 
 
Figure 31: Post mortem Methoxy-X04 staining of plaque development categories. A flower 
plaque (a, white arrowheads are ‘petal’ plaques), a plaque cluster (b) and merging plaques (c, 
white arrows).Scale bar: 25 µm 
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Discussion 
 
Clustering Hypothesis of Amyloid Plaque Development 
Plaques are one of the hallmarks of AD and are associated with toxicity of the surrounding 
tissue. This study, using a two-stage plaque staining technique, examined plaques over time 
and generated two important conclusions:  
1) New plaques are more likely to form in the vicinity of a pre-existing plaque 
thereby forming clusters of plaques 
 
2) Large plaques can have grown from several precursors showing that plaque 
clusters can fuse over time 
Together, these results built a new hypothesis of plaque development to compliment the 
uniform growth theory, namely the clustering hypothesis of plaque development. This new 
hypothesis, as illustrated by the schematic in Figure 32 explains how large plaques arise from 
clusters of multiple smaller plaques. The presented data support three different scenarios 
whereby this could happen and these are illustrated in Figure 32. In the first scenario, a new 
plaque deposits in the vicinity of the initial plaque and these two plaques grow and merge 
together over time, eventually forming a large plaque with a single core. Alternatively, those 
two neighbouring plaque cores can remain separate and the diffuse material grows around to 
create a large plaque with multiple, separate cores. In a third scenario, the initial plaque 
develops multiple neighbouring plaques (a flower plaque) and then, hypothetically, grows a 
diffuse halo and ultimately becomes a multicored plaque. By this, the presented data provide 
evidence for a clustering hypothesis of large plaque development. The clustering hypothesis 
is an alternative theory of how plaques can grow, and complements the uniform growth 
theory of plaque development (Figure 12 a). 
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Figure 32: Schematic figure of the clustering hypothesis of plaque growth. An initial single 
plaque (a) is joined by a new, very close plaque (b). These two plaques fuse over time (c) to 
produce a larger plaque with a single core (d) or remain separate (e) and grow to be a large, 
multicored plaque (g). Alternatively, the initial plaque (a) can be joined by multiple new 
neighbour plaques (f) and grow to be a large, multicored plaque (g). Solid arrows represent 
events supported by the presented data; the dashed arrow represents hypothetical plaque 
development. 
70 
 
Non-Random Location of Plaque Deposition 
The first major conclusion, that new plaques deposit close to pre-existing plaques, can be 
interpreted as evidence for the non-random location of plaque deposition. This  project was 
inspired by the finding that, plaques in brain sections from APP transgenic mice showed non-
random clustering of plaques (Urbanc et al., 1999). The presented data confirmed this result 
experimentally in a mouse model of AD; new plaques deposited < 40 µm from a pre-existing 
plaque at higher than chance level. This could be because of one of two reasons: either the 
microenvironment in which the first plaque appeared is conducive to plaque development, 
hence subsequent plaques also appear there, or, the first plaque itself somehow induces 
further plaques to develop in the vicinity. Each possibility will be discussed in turn. 
As mentioned in the introduction, the precise origin of Aβ for plaque development is 
currently under debate and many factors may influence the location of plaque formation. 
These factors may well make it more likely that a first plaque, and subsequent plaques, 
develop in a particular location of the cerebral cortex rather than even a relatively short 
distance away. For example, if the Aβ for plaques originates from the blood vessels (Fiala, 
2007), then the tissue close to blood vessels maybe particularly favourable for plaque 
development. Or, if highly active neurons promote plaque development (Bero et al., 2011), 
then the environment around highly active axon terminals may be a source of multiple 
plaques. Studies of plaque deposition in AD patients (Beach & McGeer, 1992) and transgenic 
mice (Beker et al., 2012) showed that cortical structure influences plaque deposition. This 
could also mean that some cortical areas are chemically or structurally more conducive to 
plaque deposition. These areas may secrete more Aβ than other areas, or have reduced Aβ 
clearance, leading to a build-up of Aβ and triggering plaque formation. Taken together, these 
factors show that plaque deposition occurs more favourably in certain microenvironments 
meaning that many plaques would form close to each other. 
The second reason, that plaques can encourage the further deposition of plaques, is also 
supported by a body of experimental data. Pre-existing plaques may harbour the seeding 
material to seed new plaques – be it oligomers or some other Aβ aggregates. Plaques have 
been shown to co-localise with and be surrounded by soluble Aβ oligomers (Koffie et al., 
2009), which may be the seed plaques (Langer et al., 2011). Therefore, it is possible that 
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plaques harbour the material necessary to seed new plaques and would seed new plaques in 
their direct vicinity. 
Alternatively, plaque seeding material may develop intracellularly, e.g. there is a theory that 
Aβ fibrilises intracellularly and is then released via cell lysis to form a plaque (D'Andrea et 
al., 2001). As reviewed in the introduction, plaques are toxic to neurons in the near vicinity 
(Bittner et al., 2012; McLellan et al., 2003) and can damage local cell membranes (Praprotnik 
et al., 1995). This being true, the presence of a pre-existing plaque could damage the local 
neurons, releasing intracellular plaque seeding material. Thereby a new plaque would be 
more likely to form in the vicinity of a pre-existing plaque. 
Taken together, there is a lot of evidence for the non-random deposition of new plaques. It is 
therefore possible that both factors are involved in this phenomenon, but more research is 
needed to fully elucidate the many influences on localisation of plaque deposition. 
 
Merger of Plaques over Time 
The second major conclusion of this study is that clusters of plaques can merge over time to 
form a single, large plaque. This is supported by previous studies that also found examples of 
multicored plaques (Condello et al., 2011; Rak et al., 2007). However, this thesis provided a 
detailed quantification of this plaque population and mapped their fate over time. Plaques that 
merged over time made up a sizable proportion (13%) of all large (> 300 µm2) plaques and 
~25% of these multicores merged over a four month period. It would be interesting to 
conduct a longer study to determine if more cores would merge over a longer period, or if 
some cores remain separate for very long periods, and whether there is a particular point in 
the pathological progression of plaques where cluster fusion happens.  
How and why would neighbouring plaques merge over time?  Three different possible 
scenarios could be envisioned. In the first scenario, the two plaques simply grow uniformly 
and the space between them slowly decreases so that they automatically gradually merge 
together. This scenario is certainly attractively simple, but a second scenario, whereby the 
space in between two close plaques is preferential for Aβ deposition is also intriguing. The 
surfaces of the two close plaques presumably offers lots of fibril ends to which Aβ molecules 
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can bind and elongate the fibres (Jucker & Walker, 2011). But in the space between the two 
plaques, the density of fibril ends is higher and so the probability of a ‘passing’ Aβ molecule 
to bind to a fibril within this space is higher than for it to bind to the rest of the plaques’ 
surfaces. Thereby, the amount of Aβ deposition in between the two close plaques may be 
higher than other places on the spherical plaques favouring the fusion of the two plaques. 
The third scenario is that the diffuse Aβ halo surrounding the dense cores of the two plaques 
can change conformation over time to a dense core conformation and thereby the cores merge 
over time. In fact, new dense core material was observed developing nearby and seemingly 
within diffuse Aβ material (Figure 30). It is tempting to speculate that the new cores 
emerging in the halo of diffuse Aβ had developed directly from the diffuse Aβ and that 
diffuse Aβ can change conformation into an amyloid structure. One theory, still widely 
debated, suggests that dense core plaques develop out of diffuse plaques (Fiala, 2007) and 
that diffuse Aβ deposits are the precursors to cored plaques. One study examined the 
conformation of plaques in young and aged mice using fluorescent probes and showed that 
Aβ likely changes conformation within plaques as plaques in older animals had less immature 
fibrils and more mature filaments than plaques in younger animals (Nyström et al., 2013). 
Indeed, this is discussed in (Meyer-Luehmann et al., 2008) as a reason they saw such a rapid 
formation of dense core plaques: that pre-amyloid Aβ was already present at that location and 
rapidly changed to a visible amyloid structure. The method employed in this thesis does not, 
unfortunately, have the temporal resolution to explore this possibility. It is nevertheless a 
compelling notion, and with advances in in vivo imaging techniques, this issue can hopefully 
be further investigated in the near future. 
The three scenarios discussed are all possible ways how multiple close plaques could merge 
over time, but to fully understand the precise mechanism behind merging plaques more 
experiments are needed.  
 
Data with Differences between Young and Older Mice  
There were two sets of data in this thesis where there were clear differences in shorter and 
longer incubation time groups. However, the differences in the plaque development between 
these groups are most likely due to technical artefacts as discussed below. 
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The first data set was the rotation analysis that compared data from this study to chance levels 
(Figure 23). This comparison only showed a significant result in the younger animals group. 
The two older groups – 1 month and 4 months - were not significantly different from chance 
levels. To explain this, it is important to keep in mind that the older groups have a higher 
plaque density than the younger group and this even has a significant negative correlation to 
the chance of a new plaque being close to a pre-existing plaque. This seems a plausible 
explanation for the disparity between groups – a higher plaque density makes it more likely 
that plaques will deposit by chance in the vicinity of a pre-existing plaque. Moreover, if there 
are more plaques in the cortex, then the deposition becomes more ‘general’ and more random 
as the niches that were particularly conducive to plaque development are saturated.  
Another explanation for the discrepancy between the groups in the rotation data could be that 
in the older groups, the analysis underestimates the amount of close new plaques. This 
underestimation could occur because of three reasons. Firstly, clusters of new plaques within 
the new plaque population were observed. Over the longer incubation time points, many new 
plaques are deposited. If several new plaques formed over the longer time point, some of the 
later new plaques probably formed nearby the earlier new plaques. Therefore, the method 
used here, with only two ‘snap-shots’ of plaque development, would not discern all the 
plaques that developed close to a pre-existing plaque and thereby underestimating the amount 
of close new plaques. Secondly, the older groups have larger plaques than the younger groups 
(Figure 16). The large plaques often had large diffuse halos surrounding the initial Methoxy-
X04 positive core. This could mean that subsequent plaques that formed very close to pre-
existing plaques would have been engulfed by the large plaque and would be counted as a 
single, multicored plaque (Figure 30). Thus, these new close plaques would not be counted as 
new and therefore the real amount of close new plaques in the longer time point groups was 
underestimated. Thirdly, we cannot rule out the possibility that Methoxy-X04 continues to 
label plaques after the injection and binds to new plaques, which would then not count as new 
plaques. This would also lead to an underestimation of the amount of new plaques. 
Any, or a mixture of all three explanations would lead to an underestimation of new plaques 
in later time points and therefore a bias in the rotation data for the older groups. 
The second data set with discrepancies between age groups was the analysis of the exact 
distances between new plaques and their close pre-existing plaque neighbours (Figure 26). In 
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this data set, the data from the younger animals behaving differently from the two older 
groups: the younger animals show a peak between 5 and 15 µm, followed by a drop to a 
steady plateau at 20-25 µm, whereas the two older groups show most of their new plaques 
20-25 µm away (Figure 26). Again, because of the increase in larger plaques in the older 
animals, this could obscure any very close new plaques, and therefore the older groups show 
very few very close (5-15 µm) new plaques. The younger animals have very few large 
plaques and so very close new plaques are not obscured and are still apparent. If one were to 
take out the very close distance groups, the plateau phases look very similar. Therefore, there 
doesn't appear to be any preferred location once more than 20 µm away. 
The staining artefacts discussed are likely explanations for the discrepancies seen in the two 
data sets. Further analysis with shorter incubation times might definitively address these 
issues. 
 
Aβ-plaque Associated Therapeutic Strategies 
The study of plaque formation and development is important for the advance of new, disease-
modifying treatment strategies; many therapeutics in development are based on preventing 
the formation of plaques, or removing the aggregated Aβ that has already deposited (Citron, 
2010). Therefore the results of this study and the clustering hypothesis of plaque development 
could have important implications for future AD therapeutics. 
One strategy for combating AD is to prevent aggregation of Aβ and plaque deposition. Many  
molecules that interfere with Aβ aggregation have been suggested as therapy for AD (Selkoe, 
2001). Aggregation inhibitors, such as cyclohexanehexol inhibitors (McLaurin et al., 2006), 
keep Aβ in monomeric form, rather than forming toxic oligomeric aggregates. Whether this 
would prevent further plaque formation once the disease has started and rescue the disease 
pathology requires detailed knowledge of the influences on Aβ deposition. Another strategy 
is to promote aggregation, so that Aβ quickly aggregates to amyloid fibrils and thereby also 
avoids the toxic oligomer stage – this would create more plaques, and so knowledge of how 
they form would be very useful for this line of therapy. However, as postulated by (Selkoe, 
2011), plaques may only ‘trap’ oligomeric Aβ up to a certain saturation level. Thereafter, 
once the brain is full of plaques, they may actually act as reservoirs to store Aβ oligomers and 
75 
 
increase toxicity. Detailed knowledge of plaque deposition and deposition niches could help 
develop focused therapy to prevent the formation of plaques and protect the brain from AD. 
Immunotherapy is another strategy to clear plaques from the brain parenchyma. By targeting 
Aβ, antibodies reduce the amount of Aβ available and thereby reduce the formation of 
plaques. Immunotherapy against Aβ is thought to reduce plaques by one or more of three 
mechanisms (Citron, 2010). Firstly, by activating nearby microglia to clear the plaque 
material (Bard et al., 2000). Secondly, the antibodies themselves may directly resolve the 
plaque material, but due to the low penetrance of antibodies (just 0.1% of serum level) into 
the brain (Bard et al., 2000), this mechanism seems unlikely. Thirdly, peripheral antibodies 
could capture Aβ, thereby acting as a ‘peripheral sink’ and reducing the Aβ concentration in 
the brain parenchyma and clearing plaques in that way (DeMattos et al., 2002; Dodart et al., 
2002; Marques et al., 2009). Active immunisation with aggregated Aβ42 reduced cerebral 
plaques and neuritic dystrophies in APP transgenic mice (Schenk et al., 1999), but clinical 
trials in AD patients have led to mixed results. Passive immunisation with pre-made 
antibodies is a prominent option as a cure for AD, however, this treatment has been marred 
by the side effect of micro-haemorrhages (Meyer-Luehmann et al., 2011; Pfeifer et al., 2002). 
This thesis expands knowledge of plaque deposition and formation and may help understand 
plaque clearing strategies better and target them more effectively to plaque-forming niches. 
The clustering hypothesis describes how large plaques in particular can arise and the 
formation of large plaque is particularly interesting as they have been shown to have different 
properties compared with smaller plaques. An in vivo study in mice investigating oxidative 
stress in the neurons surrounding plaques found more oxidised neurites in the vicinity of  
larger plaques (Xie et al., 2013). Assuming that plaques do host molecules that are toxic to 
neurons, then it could be argued that larger plaques are logically more toxic than smaller 
plaques. However, another study that quantified the neuritic damage surrounding plaques 
observed, that smaller, faster growing plaques are surrounded by more dystrophic neurites 
than larger plaques (Condello et al., 2011). Either way, large plaques seem to have different 
effects on the surrounding tissue to smaller plaques, and therefore knowing specifically how 
they form and grow is an important topic and may be useful in developing novel therapeutic 
strategies. 
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Concluding Remarks 
In conclusion, the presented data provide a detailed description of plaque development over 
time and gave strong in vivo support for a clustering mechanism of large plaque growth. This 
clustering hypothesis complements a uniform growth hypothesis and gives another dimension 
to our knowledge of plaque development. The data also give interesting hints that plaques 
deposit in a non-random manner and that multiple plaques do fuse over time to give rise to 
large plaques. Both are interesting phenomena and could warrant study. 
Why plaques form in clusters and how new plaques are seeded are still open questions. The 
answers to these questions and an increasing understanding of plaque formation and 
development will hopefully lead to greater understanding of the AD etiology and finally, in 
the future, to disease modifying therapies.  
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